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SCIENTIFIC OPINION 
Scientific Opinion on Dietary Reference Values for vitamin C1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) derived Dietary Reference Values (DRVs) for vitamin C. The Panel concludes that an Average 
Requirement (AR) can be derived from indicators of vitamin C status, as well as a Population Reference Intake 
(PRI) assuming a coefficient of variation (CV) of 10 %. Several health outcomes possibly associated with 
vitamin C intake were also considered but data were found to be insufficient to establish DRVs. For healthy 
adults, the AR is determined from the quantity of vitamin C that balances metabolic vitamin C losses and allows 
the maintenance of an adequate body pool characterised by fasting plasma ascorbate concentrations at around 
50 µmol/L. In men, an AR of 90 mg/day of vitamin C and a PRI of 110 mg/day are proposed. As no value for 
metabolic losses is available in women, the AR for women is extrapolated from the AR for men on the basis of 
differences in reference body weight, and an AR of 80 mg/day and a PRI of 95 mg/day are proposed. For infants 
aged 7-11 months, the Panel has decided to retain the PRI of 20 mg/day set by the SCF (1993), as no suitable 
evidence has emerged since the previous assessment. For children and adolescents, the ARs for vitamin C are 
extrapolated from the ARs for adults taking into account differences in reference body weight, and PRIs are 
derived, ranging from 20 mg/day for 1 to 3 year-old children, to 100 and 90 mg/day for boys and girls aged  
15-17 years, respectively. For pregnant and lactating women, vitamin C intakes of 10 mg/day and of 60 mg/day 
in addition to the PRI of non-pregnant non-lactating women are proposed.  
© European Food Safety Authority, 2013 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to deliver a scientific opinion on Dietary Reference Values (DRVs) 
for the European population, including vitamin C.  
Vitamin C (L-ascorbic acid) is an enzyme cofactor for biochemical reactions catalysed by 
monooxygenases, dioxygenases and mixed function oxygenases. Vitamin C plays an important role in 
the biosynthesis of collagen, is essential for the synthesis of carnitine and catecholamines, and is also 
involved in the metabolism of cholesterol to bile acids. Vitamin C in aqueous solution readily 
scavenges reactive oxygen and nitrogen species, and is part of the antioxidant network of the body.  
Gastrointestinal absorption is about 80 % for an intake of about 100 mg/day. Vitamin C is transported 
as the free anion ascorbate in plasma, and is distributed to all tissues. Biomarkers of body stores are 
related to the size and turnover of vitamin C body stores, and to the mass balance of vitamin C in the 
body. In this Opinion, plasma ascorbate concentration is considered as the primary indicator of body 
stores. The mass balance of vitamin C in the body is determined from the rate of turnover of the body 
pool, considering metabolic losses, urinary losses and the quantity of vitamin C required for the 
replacement of these losses, taking into account absorption efficiency. 
Scurvy, characterised by symptoms related to connective tissue defects, occurs in adults at a plasma 
ascorbate concentration below 10 µmol/L and a body pool less than 300 mg, and can be prevented 
with an intake of 10 mg vitamin C/day. In vitamin C-depleted men, when vitamin C intake is 
increased to 60 to 100 mg/day, plasma ascorbate concentrations steeply increase up to a value of about 
50 µmol/L, and the body pool rises to 1.0-1.5 g. When vitamin C intake is increased to above 
100 mg/day, there is a progressive flattening of the curve until plasma ascorbate reaches a plateau at 
about 70-80 µmol/L that can be maintained only by chronic ingestion of large doses of vitamin C 
above 200 mg/day. Plasma ascorbate concentrations above 10 µmol/L but below 50 µmol/L are 
indicative of a suboptimal status with a risk of insufficiency. A plasma ascorbate concentration of 
50 µmol/L is indicative of an adequate status. Urinary excretion of ascorbate is low when plasma 
ascorbate concentrations are low, but urinary excretion increases sharply for plasma concentrations 
above about 50 µmol/L, and this is assumed to reflect near-saturation of body pools.  
The Average Requirement (AR) for vitamin C in healthy adults was determined from the quantity of 
vitamin C intake that balances metabolic vitamin C losses and maintains fasting plasma ascorbate 
concentrations at about 50 µmol/L. Taking a conservative approach and based on the fact that a 
complete set of data was only available in men, the Panel selected metabolic losses of 50 mg/day, an 
absorption of 80 % and a urinary excretion of 25 % of the vitamin C intake. Thus, a mean vitamin C 
intake of 91 mg/day (rounded to 90 mg/day) was estimated to be required to balance daily losses, and 
this intake represents the AR. Assuming a coefficient of variation (CV) of 10 %, a Population 
Reference Intake (PRI) of 110 mg/day was derived for healthy men. As no value for metabolic losses 
was available in women, the AR for women was extrapolated from the AR for men. Extrapolation was 
done by isometric scaling (linear with body weight), since vitamin C is considered to be distributed 
throughout the whole body, since the multi-compartment models used to calculate the metabolic losses 
in men consider an exchange with only one whole body tissue pool, since few sex-related differences 
could be observed in the pharmacokinetics of vitamin C, and since a main part of the observed 
differences can be explained by body weight differences between sexes. This calculation led to an AR 
of 78 mg/day (rounded to 80 mg/day) for women. Assuming a CV of 10 % and rounding to the 
closest 5, a PRI of 95 mg/day of vitamin C was derived for healthy women. Because of a scarcity of 
data on the influence of ageing, the Panel concluded that there were insufficient data to derive 
different DRVs for vitamin C for older adults compared to younger adults.  
The Panel also considered several health outcomes that may be associated with vitamin C intake. The 
Panel decided that the available data on the effects of vitamin C intake and/or status on scurvy, blood 
lipids and blood pressure, common cold, and on chronic disease-related outcomes (cardiovascular 
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disease-related, cancer, vision-related, mortality) could not be used as criteria to derive the 
requirement for vitamin C. 
For infants aged 7-11 months, the Panel decided to retain the PRI of 20 mg/day set by the Scientific 
Committee for Food (SCF, 1993), as no suitable evidence has emerged since the previous assessment. 
For children and adolescents, the AR for vitamin C was extrapolated from the ARs for adults taking 
into account differences in body weight (isometric scaling). The PRIs were derived by assuming a CV 
of 10 % and range from 20 mg/day for 1 to 3-year-old children, to 100 and 90 mg/day for boys and 
girls aged 15-17 years, respectively. 
In pregnancy, plasma ascorbate concentration decreases because of haemodilution and active transfer 
to the fetus. For pregnant women, a vitamin C intake of 10 mg/day in addition to the PRI of non-
pregnant women was proposed. In lactating women, the amount of vitamin C secreted in breast milk 
reflects maternal vitamin C intake rather than the infant’s requirement. For women exclusively 
breastfeeding during the first six months post partum, a vitamin C intake of 60 mg/day, in addition to 
the PRI of non-lactating women, was proposed to cover vitamin C losses in breast milk. 
The main contributors to the vitamin C intake of adults are fruits and vegetables and their juices, and 
potatoes. Data from dietary surveys show that average vitamin C intakes from food only in European 
countries range from 69 to 130 mg/day in men and from 65 to 138 mg/day in women.  
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The scientific advice on nutrient intakes is important as the basis of Community action in the field of 
nutrition, for example such advice has in the past been used as the basis of nutrition labelling. The 
Scientific Committee for Food (SCF) report on nutrient and energy intakes for the European 
Community dates from 1993. There is a need to review and if necessary to update these earlier 
recommendations to ensure that the Community action in the area of nutrition is underpinned by the 
latest scientific advice.  
In 1993, the SCF adopted an opinion on nutrient and energy intakes for the European Community4. 
The report provided Reference Intakes for energy, certain macronutrients and micronutrients, but it did 
not include certain substances of physiological importance, for example dietary fibre. 
Since then, new scientific data have become available for some of the nutrients, and scientific advisory 
bodies in many European Union Member States and in the United States have reported on 
recommended dietary intakes. For a number of nutrients, these newly established (national) 
recommendations differ from the reference intakes in the SCF (1993) report. Although there is 
considerable consensus between these newly derived (national) recommendations, differing opinions 
remain on some of the recommendations. Therefore, there is a need to review the existing EU 
Reference Intakes in the light of new scientific evidence, and taking into account the more recently 
reported national recommendations. There is also a need to include dietary components that were not 
covered in the SCF opinion of 1993, such as dietary fibre, and to consider whether it might be 
appropriate to establish reference intakes for other (essential) substances with a physiological effect. 
In this context, EFSA is requested to consider the existing Population Reference Intakes for energy, 
micro- and macronutrients and certain other dietary components, to review and complete the SCF 
recommendations, in the light of new evidence, and in addition advise on a Population Reference 
Intake for dietary fibre.  
For communication of nutrition and healthy eating messages to the public it is generally more 
appropriate to express recommendations for the intake of individual nutrients or substances in food-
based terms. In this context, EFSA is asked to provide assistance on the translation of nutrient based 
recommendations for a healthy diet into food based recommendations intended for the population as a 
whole.  
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
In accordance with Article 29 (1)(a) and Article 31 of Regulation (EC) No. 178/2002, the Commission 
requests EFSA to review the existing advice of the Scientific Committee for Food on population 
reference intakes for energy, nutrients and other substances with a nutritional or physiological effect in 
the context of a balanced diet which, when part of an overall healthy lifestyle, contribute to good 
health through optimal nutrition.  
In the first instance, EFSA is asked to provide advice on energy, macronutrients and dietary fibre. 
Specifically, advice is requested on the following dietary components:  
• Carbohydrates, including sugars; 
• Fats, including saturated fatty acids, polyunsaturated fatty acids and monounsaturated fatty 
acids, trans fatty acids; 
• Protein; 
                                                     
4  Scientific Committee for Food, Nutrient and energy intakes for the European Community, Reports of the Scientific 
Committee for Food 31st series, Office for Official Publication of the European Communities, Luxembourg, 1993. 
Dietary Reference Values for vitamin C
 
EFSA Journal 2013;11(11):3418 7
• Dietary fibre. 
Following on from the first part of the task, EFSA is asked to advise on population reference intakes 
of micronutrients in the diet and, if considered appropriate, other essential substances with a 
nutritional or physiological effect in the context of a balanced diet which, when part of an overall 
healthy lifestyle, contribute to good health through optimal nutrition. 
Finally, EFSA is asked to provide guidance on the translation of nutrient based dietary advice into 
guidance, intended for the European population as a whole, on the contribution of different foods or 
categories of foods to an overall diet that would help to maintain good health through optimal nutrition 
(food-based dietary guidelines). 
Dietary Reference Values for vitamin C
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ASSESSMENT 
1. Introduction 
Vitamin C (L-ascorbic acid) is a water-soluble organic compound that is needed for normal metabolic 
functioning of the body. Vitamin C is an essential component of the diet, as humans and other 
primates have lost the ability to synthesise vitamin C via the glucuronic acid pathway.  
In 1993, the Scientific Committee for Food (SCF) adopted an opinion on nutrient and energy intakes 
for the European Community and derived for vitamin C a Lowest Threshold Intake (LTI), an Average 
Requirement (AR) and a Population Reference Intake (PRI) for adults. The SCF also set PRIs for 
infants aged 6-11 months and for children. For pregnancy and lactation, additional intakes to be added 
to the PRI for non-pregnant non-lactating women were proposed.  
2. Definition/category 
2.1. Chemistry 
Vitamin C is a 6-carbon hydroxy-lactone that is structurally related to glucose and has a molecular 
mass of 176.12 Da. Vitamin C refers to both ascorbic acid and dehydroascorbic acid. Ascorbic acid is 
readily oxidised to L-dehydroascorbic acid, in which the 3,4-dihydroxy groups are replaced by 3,4-
diketone functions, and L-dehydroascorbic acid can be reduced back to ascorbic acid. Vitamin C in 
solution can be oxidised and donate electrons to oxidants, including oxygen and metal ions, to give an 
equilibrium mixture of ascorbic and dehydroascorbic acids. 
2.2. Functions of vitamin C 
Vitamin C has a number of biochemical and physiological functions in the body which are largely 
dependent on its ability to provide reducing equivalents in various biochemical reactions (Burri and 
Jacob, 1997; Tsao, 1997). 
2.2.1. Vitamin C as cosubstrate of enzymatic reactions 
Vitamin C is an enzyme cofactor for biochemical reactions catalysed by monooxygenases, 
dioxygenases and mixed function oxygenases. Vitamin C acts as an electron donor with a redox 
potential that reduces the active centre metal ion of mono- and dioxygenases and maintains metal ions 
in a reduced state for optimal activity of the enzyme (Burri and Jacob, 1997; Tsao, 1997). 
Vitamin C plays an important role in the biosynthesis of collagen, which represents about one quarter 
of the total body protein and constitutes the principal protein of skin, bones, teeth, and connective 
tissues. Procollagen-proline dioxygenase (proline hydroxylase) and procollagen-lysine 5-dioxygenase 
(lysine hydroxylase), two enzymes involved in procollagen biosynthesis, require vitamin C for 
maximal activity (Phillips and Yeowell, 1997). Vitamin C deficiency impairs collagen synthesis. 
Vitamin C is essential for the synthesis of carnitine (Hulse et al., 1978), as cofactor of two 
dioxygenases involved in carnitine biosynthesis (Burri and Jacob, 1997; Vaz and Wanders, 2002).  
Vitamin C is also a cofactor for catecholamine biosynthesis, in particular the conversion of dopamine 
to noradrenaline catalysed by dopamine β-monooxygenase (Burri and Jacob, 1997).   
Vitamin C is involved in the metabolism of cholesterol to bile acids via the enzyme cholesterol  
7α-monooxygenase, and in steroid metabolism in the adrenal glands (Burri and Jacob, 1997; Tsao, 
1997). In vitamin C deficiency, the metabolism of cholesterol to bile acids is slowed down in guinea 
pigs, resulting in an accumulation of cholesterol in the liver, hypercholesterolaemia and formation of 
cholesterol gall stones (Ginter et al., 1982).  
Dietary Reference Values for vitamin C
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Hydroxylation of aromatic drugs and carcinogens by hepatic cytochrome P450 is enhanced by 
reducing agents such as vitamin C (Tsao, 1997). 
The activities of several other enzymes are also known to be dependent on vitamin C, including the 
mono- and dioxygenases involved in peptide amidations that are necessary for maximal activity of the 
hormones oxytocin, vasopressin, cholecystokinin and α-melanocyte-stimulating hormone (Cameron 
and Pauling, 1973), and the hydroxylation of phenylalanine in tyrosine formation (Burri and Jacob, 
1997; Tsao, 1997). 
2.2.2. Vitamin C as a reducing and antioxidant agent 
Besides its ability to provide reducing equivalents for a variety of biochemical reactions, vitamin C 
functions physiologically as a water-soluble antioxidant acting as a free radical scavenger (Sadler et 
al., 1999; IOM, 2000). Vitamin C readily scavenges reactive oxygen species and reactive nitrogen 
species, as well as singlet oxygen and hypochlorite. The one- and two-electron oxidation products are 
easily regenerated by glutathione and NADH or NADPH (IOM, 2000). 
Vitamin C is part of the antioxidant defence system, which is a complex network including 
endogenous and dietary antioxidants, antioxidant enzymes, and repair mechanisms, with mutual 
interactions and synergetic effects among the various components. L-ascorbic acid is able to 
regenerate urate, glutathione, and beta-carotene from their respective one-electron oxidation products 
(Edge and Truscott, 1997; Phillips and Yeowell, 1997) and α-tocopherol (vitamin E) from the  
α-tocopheroxyl radical produced via scavenging of lipid radicals (Bowry et al., 1995; Packer, 1997). 
Vitamin C is considered to be involved in the maintenance of endothelial function possibly through its 
antioxidant effects (IOM, 2000). The reducing capacity of vitamin C has also been implicated in 
enhancing gastrointestinal absorption of dietary non-haem iron (Hallberg, 1981; Bendich and Cohen, 
1990; Burri and Jacob, 1997).  
2.2.3. Health consequences of vitamin C deficiency and excess 
2.2.3.1. Deficiency 
A continuous lack of vitamin C in the diet causes the disease scurvy, which occurs in adults at a 
plasma ascorbate concentration below 10 µmol/L and a body pool less than 300 mg (Baker EM et al., 
1971; Levine, 1986; Weber et al., 1996; Burri and Jacob, 1997). Scurvy is characterised by symptoms 
related to connective tissue defects that result from a weakening of collagenous structures. In infants, 
there may be important effects on bone tissue with impaired bone growth and ossification (Shenkin, 
2008). In adults, scurvy is associated with tooth loss, joint pain, bone and connective tissue disorders, 
and poor wound healing with multiple clinical features including petechiae, bruising, and inflamed and 
bleeding gums. Depression, hypochondria, and mood changes are frequently associated with scurvy 
and may be related to deficient dopamine hydroxylation. Scurvy can be prevented with a vitamin C 
intake of 10 mg/day (Baker EM et al., 1971; Levine, 1986; Weber et al., 1996; Burri and Jacob, 1997). 
Early or prescorbutic symptoms also include fatigue, lethargy, anaemia, aching joints, and muscle 
weakness (Lukaski, 2004). It has been suggested that fatigue and lethargy may be related in part to 
insufficient carnitine biosynthesis, and consequently deficient transport of activated long chain fatty 
acids into the mitochondria for energy generation (Davies et al., 1987; Jacob and Pianalto, 1997) (see 
Section 2.4.3.2.). 
2.2.3.2. Excess  
EFSA did not set any Tolerable Upper Intake Level (UL) for vitamin C. The limited available data 
from studies in animals and humans were considered to suggest a low acute toxicity of vitamin C 
(Johnston, 1999; EFSA, 2004). Relationships between vitamin C intakes and adverse gastrointestinal 
effects or renal effects in relation to urinary excretion of oxalate were assessed, and reversible acute 
gastrointestinal intolerance or diarrhoea was regarded as the most clearly defined adverse effect at 
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high intakes (3-4 g/day). However, data on a dose-response relationship for adults (including older 
adults) or for children were considered to be insufficient (EFSA, 2004). Despite the extensive use of 
high doses of vitamin C in supplements, there were only a limited number of controlled studies that 
specifically investigated adverse effects.  
It has been suggested that vitamin C may also exert pro-oxidant effects by reducing ferric to ferrous 
ion, and that this might stimulate uptake of iron from the gut as iron is absorbed in the reduced state 
(Wollenberg and Rummel, 1987). In addition, an increase in free iron concentration through 
vitamin C’s ability to release ferrous ions from ferritin (Halliwell and Gutteridge, 1989) may promote 
the generation of free radicals through the Fenton reaction (Prousek, 2007). Whether excess vitamin C 
intake leads to these mechanisms in vivo is uncertain (Carr A and Frei B, 1999). 
2.3. Physiology and metabolism of vitamin C 
The schematic relationship between vitamin C intake, vitamin C accumulation in the body and 
vitamin C elimination is shown in Figure 1. The four parts of this figure will be described in the 
following sub-sections.  
 
Figure 1:  Schematic view of vitamin C kinetics in the body with the relationship between vitamin C 
intake, plasma concentration, body stores and urinary excretion in healthy male adults (adapted from 
Kallner et al. (1979); Graumlich et al. (1997)). 
2.3.1. Intestinal absorption 
Vitamin C is absorbed in the small intestine via a sodium-dependent active transport mechanism 
(Tsao, 1997; Rumsey and Levine, 1998). The efficiency of intestinal absorption of vitamin C is 80-
90 % at dietary intakes of 30-180 mg/day (SCF, 1993). Because the transporter is saturable, absorption 
efficiency gradually decreases at higher intakes (Kallner et al., 1979; Hornig and Moser, 1981; 
Blanchard et al., 1997; EFSA, 2004). 
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Two depletion-repletion studies (Baker et al., 1969; Baker EM et al., 1971) using a radio-labelled 
vitamin C dose were each undertaken in six healthy men of unknown age and smoking status. After 
the depletion phase (0-2.5 mg/day vitamin C), total vitamin C intake of the completers was increased 
to 4 to 66.5 mg/day (n = 4 completers) (Baker et al., 1969), or 6.5 to 130.5 mg/day (n = 5 completers) 
(Baker et al., 1971). Ingested radioactivity was excreted in urine and faeces except for less than 2 % of 
radioactivity which was expired as carbon dioxide. Faecal excreta accounted for not more than 2 % of 
the radioactivity excreted, thus absorption was about 98 % of intake.  
In another study (Kallner et al., 1977), seven healthy non-smoking men of unknown age followed a 
diet low in vitamin C for nine days, were then orally supplemented with 90 mg (n = 5) or 180 mg 
(n = 2) of vitamin C daily for two weeks before oral administration of 30 mg (n = 5) or 60 mg (n = 2) 
of radio-labelled vitamin C. The vitamin C intake was then increased to four daily doses of 1 000 mg 
and the cumulative excretion of radioactivity in the urine was measured over a period of ten days. The 
average absorption was estimated to amount to 80-90 % of the labelled doses (30 mg or 60 mg). 
Hornig et al. (1980) consecutively administered two daily doses of 1, 2, 3 and 4 g of vitamin C to a 
non-smoking man of unknown age, followed by 5 g/day of vitamin C for ten days. The mean daily 
urinary excretion of ascorbate was used to estimate the absorption of vitamin C, which decreased from 
75 % (1 g) to about 44 % (2 g), 39 % (3 g), 28 % (4 g) and 21 % (5 g) of the ingested dose.  
Using data collected over three years on healthy men (n = 50) and women (n = 25) (no age given) 
receiving single oral doses of vitamin C (Kübler and Gehler, 1970), i.e. 1.5 g (n = 16), 3 g (n = 29), 
6 g (n = 11), or 12 g (n = 19), and for which serum ascorbate and, for some subjects (n = 25), urinary 
ascorbate concentrations were measured, vitamin C absorption was calculated using a pharmacokinetic 
model (Kübler, 1970) based on the data measured in plasma and urine. Mean absorption decreased 
from about 50 % for an intake of 1.5 g to about 16 % for a vitamin C intake of 12 g. 
In a depletion-repletion study using a pharmacokinetic model, seven healthy men aged 20-26 years 
with unknown smoking status followed a diet containing 60 mg vitamin C/day for three weeks, 
followed by a diet with less than 5 mg/day for the entire study (Graumlich et al., 1997). The depletion 
phase of unknown duration was followed by a repletion phase using oral doses of 15, 30, 50, 100, 200, 
500, and 1 250 mg twice daily. Each dose was applied for several days with the aim of reaching a new 
steady state. At that time, a one-day absorption test was performed, which involved oral administration 
of half of the dose given so far followed by intravenous administration of the other half of the dose. 
Using a multi-compartment model, the mean fractional absorption derived from oral versus 
intravenous vitamin C administration was reported to be 86 % for 15 mg/day, 85 % for 30 mg/day, 
84 % for 50 mg/day, 81 % for 100 mg/day, 78 % for 200 mg/day, 75 % for 500 mg/day, and 62 % for 
1 250 mg/day. 
The Panel notes that data on vitamin C absorption have mainly been collected in men, that absorption 
is about 80 % for an intake of 100 mg/day and about 75 % for an intake of 1 g/day, and that the 
efficiency of absorption decreases with increasing doses.  
2.3.2. Transport in blood and variability of plasma concentrations 
In plasma, vitamin C is transported as the free anion ascorbate5, and no specific binding protein has 
been identified.  
When the daily vitamin C intake increases, plasma ascorbate concentration increases according to a 
sigmoidal profile (Sauberlich, 1975; Irwin and Hutchins, 1976; Kallner et al., 1979; Basu and Schorah, 
1982; Polidori et al., 2004; Levine et al., 2011). In depleted subjects with low plasma ascorbate, when 
vitamin C intake is increased, plasma ascorbate concentration is characterised by a steep rise up to a 
value of about 50 µmol/L which is reached for a vitamin C intake between 60 and 100 mg/day (Basu 
                                                     
5  In this Opinion, plasma ascorbate concentration is expressed in µmol/L. Published values expressed in another unit 
(e.g. mg/100 mL) have thus been converted to µmol/L. 
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and Schorah, 1982; Levine et al., 1996; Levine et al., 2001). When vitamin C intake is increased above 
100 mg/day, there is a progressive flattening of the curve until it reaches a plateau at about  
70-80 µmol/L. These high plasma concentrations can only be maintained by chronic ingestion of doses 
of vitamin C above 200 mg/day (Figure 1). 
According to depletion-repletion studies undertaken in 15 healthy non-smoking women aged 19-
27 years (Levine et al., 2001) and in seven healthy non-smoking men aged 20-26 years (Levine et al., 
1996) receiving in the repletion phase increasing doses of vitamin C (30, 60, 100, 200, 400, 1 000, 
2 500 mg/day, half of the dose ingested twice daily), women reach the plateau of plasma ascorbate 
concentration at a lower vitamin C intake than men, but the value of the plasma concentration at the 
plateau is similar in women and men (Levine et al., 2011). Depletion and repletion profiles of 
vitamin C were determined in four groups of healthy non-smoking non-institutionalised men (aged 21-
28 (n = 15) or 66-74 years (n = 15)) and women (aged 20-29 (n = 14) or 65-72 years (n = 14)) 
(Blanchard, 1991b). Plasma ascorbate concentrations were determined upon entry into the study, once 
each week during a five-week period of dietary restriction of vitamin C (< 10 mg/day) and twice each 
week during a 2.5 to 3-week period of supplementation with 500 mg/day. Mean baseline, depleted and 
repleted plasma ascorbate concentrations did not differ between young and elderly subjects. Depleted 
plasma ascorbate concentrations did not differ between males and females, whereas mean repleted 
plasma ascorbate concentrations were significantly higher in women (about 95 and 102 µmol/L in 
young and elderly women, respectively) than in men (about 80 and 83 µmol/L in young and elderly 
men, respectively).  
An observational study in 28 pregnant adolescents (n = 28) and 74 pregnant women showed that mean 
plasma ascorbate concentrations significantly decreased in the course of pregnancy, from about 
80 µmol/L at < 14 weeks of gestation (58 samples) to about 70 µmol/L at 39-42 weeks of gestation 
(six samples) (Morse et al., 1975). This decrease may be related to haemodilution and active transfer 
to the fetus, as suggested from an in vitro study (Choi and Rose, 1989). A decrease in plasma 
ascorbate concentration was also observed in a Scottish population of pregnant women (n = 1 007), 
from about 64 µmol/L (median: 12 weeks of pregnancy) to 37 µmol/L at delivery (Scaife et al., 2006). 
In smokers, plasma/serum ascorbate concentration is usually lower compared to non-smokers. An 
observational study showed that the risk of having a plasma ascorbate concentration below 11 µmol/L 
was significantly higher in male or female smokers compared to non-smokers (Hampl et al., 2004). 
Plasma ascorbate concentrations increased in subjects who quit smoking compared to smokers of at 
least 15 cigarettes/day for one year (Lykkesfeldt et al., 1996). A lower plasma/serum ascorbate 
concentration is observed in smokers even after adjustment for differences in vitamin C intakes. An 
observational study showed that plasma ascorbate concentrations in tobacco chewers (n = 11) and 
cigarette smokers (n = 23) were significantly lower than in non-smokers (n = 10), while vitamin C 
intake was not statistically different between groups (Giraud et al., 1995). Data collected from 
459 men aged 20-60 years, including 146 non-smokers, 125 former smokers, and 188 current smokers 
(< 20 cigarettes/day, n = 104; ≥ 20 cigarettes/day, n = 84) showed that vitamin C intake was lower in 
smokers of ≥ 20 cigarettes/day compared to the other groups, and that plasma ascorbate concentration 
was significantly different between groups (even after adjustment for confounders including vitamin 
intake), being higher in non-smokers, lower in smokers of ≥ 20 cigarettes/day, but not significantly 
different between ex-smokers and smokers of < 20 cigarettes/day (Marangon et al., 1998). 
The Panel notes that when daily vitamin C intake increases, plasma ascorbate concentration increases 
according to a sigmoidal profile in healthy adult men. This is characterised by a steep rise of plasma 
ascorbate up to a concentration of about 50 µmol/L reached for an intake between 60 and 100 mg/day, 
and by a progressive flattening of the curve until it reaches a plateau at about 70-80 µmol/L for higher 
vitamin C intakes. The Panel also notes that women reach the plateau of plasma ascorbate 
concentration at a lower vitamin C intake than men, but that the value of the plasma concentration at 
the plateau is similar in women and men, that plasma ascorbate concentration decreases during 
pregnancy, and that it is lower in smokers compared to non-smokers. 
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2.3.3. Distribution to tissues and metabolism 
Vitamin C is distributed to all tissues. Vitamin C is efficiently transported into the cell in its reduced 
(ascorbate) and oxidised (dehydroascorbate) forms by active and facilitative transport systems, 
respectively (Tsao, 1997; Jacob, 1999; Linster and Van Schaftingen, 2007). The cellular transport of 
ascorbate is mediated by two active sodium-dependent cotransporters, SVCT1 and SVCT2, which 
show distinct tissue distribution and vary by cell type. Dehydroascorbate is transported by glucose 
transporters, particularly GLUT1, GLUT3 and GLUT4, and the transport is therefore not directly 
energetically driven, but dehydroascorbate is readily converted in the cell to ascorbate and this 
reductive step drives its intracellular uptake.  
Per 100 g of wet tissue, higher concentrations are found in the pituitary glands (40-50 mg), the adrenal 
glands (30-40 mg), the eye lens (25-31 mg) and the brain (13-15 mg) than in the plasma (0.4-1.0 mg), 
saliva (0.07-0.09 mg), kidney (5-15 mg) and skeletal muscle tissue (up to 4 mg) (Hornig, 1975; Carr et 
al., 2013).  
In an intervention study (Carr et al., 2013), 36 non-smoking men were randomly assigned to receive 
for six weeks either 0.5 or 2 kiwifruit/day. A significant correlation between the ascorbate 
concentration in skeletal muscle (vastus lateralis) measured by biopsies and fasting plasma ascorbate 
concentration was observed. In addition, mean muscle ascorbate concentration was significantly 
higher in the second plasma ascorbate quintile (21-36 µmol/L) compared to the first one (4-
20 µmol/L), and in the fourth quintile (48-58 µmol/L) compared to the third one (37-47 µmol/L), but 
not significantly different between the second and third quintiles, nor between the fourth and the fifth 
(59-82 µmol/L) quintiles. The Panel notes that there was no additional increase in muscle ascorbate 
concentration in non-smoking men at a plasma ascorbate concentration above around 50 µmol/L. 
Accumulation of vitamin C into neutrophils and lymphocytes is mediated by both low affinity and 
high affinity transport processes. At steady state, the relationship between vitamin C intake and 
ascorbate concentration in circulating cells (neutrophils, monocytes, platelets, lymphocytes) parallels 
that between vitamin C intake and ascorbate concentration in plasma in adult men and women (Basu 
and Schorah, 1982; Levine et al., 1996; Levine et al., 2001). Curves of intracellular ascorbate 
concentrations as a function of vitamin C doses in healthy non-smoking men (Levine et al., 1996) and 
women (Levine et al., 2001) showed that plateaus were reached at doses of about 100-400 mg/day in 
neutrophils (about 1.3 mmol/L), monocytes (about 3 mmol/L), platelets (about 3.5 mmol/L in women) 
and lymphocytes (about 3.5-4 mmol/L). 
In mammals, the degradation of ascorbate proceeds via dehydroascorbate which is an unstable 
molecule, and involves spontaneous and possibly enzyme-catalysed reactions (Linster and Van 
Schaftingen, 2007). In the body, vitamin C is readily oxidised to dehydroascorbate, which can be 
reduced back to ascorbate or irreversibly hydrolysed to diketogulonic acid and then metabolised to 
oxalate, threonic acid, xylose, xylonic acid and lyxonic acid (Basu and Dickerson, 1996). In human 
subjects injected with labelled ascorbate, an average of 44 % of the total radioactivity excreted in urine 
was recovered as oxalate, other urinary metabolites including 2,3-diketo-l-gulonate and 
dehydroascorbate (Hellman and Burns, 1958), and little, if any, radioactivity was recovered as carbon 
dioxide. Oxidation to carbon dioxide occurs at high doses of intake, partly because of the catabolism 
of unabsorbed vitamin C by the intestinal microflora (Kallner et al., 1985). Ascorbate may also 
undergo limited conjugation with sulphate to form ascorbate-sulphate, which is excreted in the urine 
(Baker EM, 3rd et al., 1971). 
2.3.4. Body stores and metabolic losses 
Depending on intake, the total body pool of vitamin C in adult men varies from less than 0.3 g to 
around 1.5-2.0 g as derived from pharmacokinetic models (Kallner et al., 1979; Sauberlich, 1990). As 
for plasma and circulating cells, there is a non-linear relationship between daily vitamin C intake and 
body stores of vitamin C. A usual intake of vitamin C below 10 mg/day is associated at steady state 
with a body pool of less than 300 mg and scurvy (see Section 2.2.3.1.). When usual vitamin C intake is 
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increased from 10 mg/day to 60-100 mg/day, the body pool rises at steady state to 1.0-1.5 g (Baker 
EM et al., 1971; Kallner, 1987). An increase in vitamin C intake to above 200 mg/day induces a 
progressive increase in body stores that plateau at values of about 1.5-2.0 g (Kallner et al., 1979 ; 
Kallner, 1987). Measurement of the vitamin C body pool is complex, since the body has a wide range 
of inter-connected ascorbate pools, each with complex kinetic properties (Fairweather-Tait, 2011; 
EURRECA, online). 
In the two depletion-repletion studies by Baker et al. using 14C-labelled ascorbic acid in men (see 
Section 2.3.1.), the depletion phase lasted for days 1-99 (Baker et al., 1969), or between day 14 and 
day 97 to 110 according to subject after a control phase of 13 days (Baker et al., 1971), and was 
followed by the repletion phase and, in one of the studies (Baker et al., 1971), by a phase of ad libitum 
diet plus supplementation of either 350 or 600 mg vitamin C/day. Individual daily metabolic losses 
were calculated from the slope of the urinary excretion curve of radioactivity during the depletion 
period following a period of adaptation to controlled levels of vitamin C intakes. Daily metabolic 
losses varied from 2.6 to 4.1 % (average: 3.2 ± 1.0 %, n = 5 completers) (Baker EM et al., 1971) and 
from 2.2 to 2.7 % ((Baker et al., 1969) reported in Baker EM et al. (1971), n = 4 completers). Pooling 
the individual data from these nine subjects, the average daily metabolic losses were 2.9 ± 0.6 %. The 
Panel notes that this would correspond to metabolic losses of 43.5 ± 9 mg/day for a saturated body 
pool of 1.5 g.  
Metabolic losses were also investigated in 15 healthy non-smoking men (20-45 years) who received, 
during a period of three weeks, a diet devoid of vitamin C and capsules of vitamin C (1 x 30 mg/day 
for n = 4, 2 x 30 mg/day for n = 4, 2 x 45 mg/day for n = 3, 4 x 45 mg/day for n = 4), in order to 
achieve a steady state condition before oral administration of a single dose of 14C-labelled ascorbic 
acid (Kallner et al., 1979). A high vitamin C dosage period was then followed for one week in order to 
wash-out the radioactivity. The time course of radioactivity was measured in plasma and urine, and 
pharmacokinetic parameters were calculated. Mean plasma steady state concentrations reported for 
14 subjects were about 14-66 µmol/L. Total turnover of vitamin C reflected the absorbed amount of 
vitamin C, and corresponded to the sum of renal losses of unmetabolised ascorbic acid and metabolic 
losses. The curve of metabolic losses as a function of total turnover of vitamin C showed saturation of 
metabolic losses at about 40 to 50 mg/day, for a total vitamin C turnover above 60 mg/day. The curve 
of plasma ascorbate concentration as a function of total vitamin C turnover showed that a total 
vitamin C turnover of about 60 mg/day corresponded to a plasma concentration of about 45-
50 µmol/L. 
In a depletion-repletion study in seven young men with unknown smoking status using a 
pharmacokinetic model (see Section 2.3.1.), maximum metabolic losses of 42 mg/day were calculated 
using parameters from the multi-compartment model (Graumlich et al., 1997).  
In smokers, higher metabolic losses are observed as a result of increased oxidative stress (IOM, 2000). 
Kallner et al. (1981) compared data from 17 healthy men (aged 21-69 years) who had been chronic 
smokers for many years and smoked more than 20 cigarettes per day to data previously collected in 
non-smoking men (Kallner et al., 1979). Smokers followed the same protocol as the non-smokers, 
including the oral administration of capsules of vitamin C (1 x 30 mg/day for n = 4, 2 x 30 mg/day for 
n = 5, 2 x 45 mg/day for n = 3, 4 x 45 mg/day for n = 5). No attempts were made to estimate the 
smoking intensity from analyses of body fluids, but standardisation of smoking was attempted by 
requesting at least one cigarette before the daily blood sampling and continued smoking during the 
administration of the labelled ascorbate. Mean plasma steady state concentrations were about  
14-89 µmol/L in smokers. The curves of the steady state plasma concentration of unlabelled ascorbate 
as a function of total turnover showed that higher total turnovers are required in smokers to achieve 
plasma concentrations comparable to those in non-smokers. Metabolic losses varied from 50.2 to 
114.0 mg/day in smokers, except for one subject at 29.6 mg/day, whereas it varied from 13.7 to 
47.6 mg/day in non-smokers. The curve of metabolic losses as a function of plasma steady state 
concentration in smokers and non-smokers showed that smokers had higher metabolic losses than non-
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smokers at a corresponding plasma ascorbate concentration. Similarly, the curve of metabolic losses as 
a function of total turnover of vitamin C was above that obtained in non-smokers. 
The Panel notes that in healthy non-smoking men aged 20-45 years, maximum metabolic losses of 
vitamin C were estimated to be about 40-50 mg/day, which corresponds to a plasma ascorbate 
concentration of about 45-50 µmol/L. The Panel also notes that no data on metabolic losses are 
available for women, and that smokers have higher metabolic losses compared to non-smokers at 
similar vitamin C intakes. 
2.3.5. Elimination 
2.3.5.1. Faeces 
Unabsorbed vitamin C can be found in the faeces (see Section 2.3.1.), but there is no indication that 
faeces constitute an important route of excretion for absorbed vitamin C. 
2.3.5.2. Urine 
Unchanged ascorbate and its metabolites are mainly excreted in the urine. There is an increasing renal 
elimination of ascorbate with an increase in plasma ascorbate concentration and/or vitamin C intake. 
This results in an inverse relationship between the elimination half-life and the dosage because of 
saturation of renal tubular reabsorption (Baker EM et al., 1971; Kallner et al., 1979; Blanchard et al., 
1997; Graumlich et al., 1997; Fukuwatari and Shibata, 2008; Uchida et al., 2011; Carr et al., 2012). 
In 19 healthy adults (Friedman et al., 1940), the curve of the relationship between urinary ascorbate 
and plasma ascorbate concentration showed that urinary ascorbate excretion increases for a plasma 
ascorbate concentration above about 45-55 µmol/L. 
In 15 healthy non-smoking men (Kallner et al., 1979) (see Section 2.3.4.), the curve of renal turnover 
as a function of steady state plasma ascorbate showed that the renal absorptive capacity was exceeded 
at plasma concentrations above about 45-50 µmol/L, with a progressive steep increase in renal 
excretion. Although the exact amount of ingested dietary ascorbic acid was unknown, analysis of 
urines for labelled ascorbic acid showed that even at low doses appreciable amounts of unmetabolised 
ascorbic acid (about 10 % of total urinary radioactivity as radio-labelled ascorbic acid) were excreted 
and this was increased to 60-80 % for higher doses. When smoking men (Kallner et al., 1981) were 
compared to non-smoking men (Kallner et al., 1979) (see Section 2.3.4.), the curves of renal turnover 
as a function of steady state plasma ascorbate concentration in smokers and non-smokers were similar. 
In a depletion-repletion study in seven young men (Graumlich et al., 1997) (see Section 2.3.1.), the 
curve of urinary ascorbate excretion as a function of plasma ascorbate concentration showed a 
progressive increase above a plasma ascorbate concentration of about 50-60 µmol/L, up to about 
600 mg ascorbate excretion for the highest single oral dose of 1 250 mg (i.e. at a plasma ascorbate 
concentration of about 80 µmol/L). There was no measurable ascorbate in urine after oral vitamin C 
doses of 15 or 30 mg. However, all subjects excreted ascorbate in the urine for oral doses of 100 mg or 
above. 
In a study conducted in 60 non-smoking men aged 18–30 years consuming sequentially half, one, two 
and three Gold kiwifruit per day for four to six weeks each, correlation of plasma ascorbate with 
urinary ascorbate also showed a marked increase in urinary output at plasma ascorbate concentrations 
above 50-60 μmol/L (Carr et al., 2012). 
According to a depletion-repletion study (Levine et al., 1996) (see Section 2.3.2.) undertaken in seven 
healthy non-smoking men, less than 0.4 mg/day of ascorbate appeared in urine of all volunteers after 
single oral vitamin C doses of 15 and 30 mg, six of seven subjects had less than 0.4 mg/day of 
ascorbate in urine after a single dose of 50 mg, but a single oral dose of 100 mg induced a urinary 
ascorbate excretion of about 25 mg. The curve of urinary excretion as a function of dose showed a 
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progressive increase up to about 600 mg ascorbate excretion for the highest single oral dose of 
1 250 mg.  
A depletion-repletion study in 15 healthy non-smoking women (Levine et al., 2001) (see Section 
2.3.2.) showed that the relationship between vitamin C intake and urinary excretion followed the same 
profile as in men. 
The Panel notes that urine is the main route of elimination of ascorbate in adults, and that at an intake 
of 100 mg/day approximately 25 % of the ingested dose of vitamin C is excreted in urine. The Panel 
also notes that ascorbate is excreted in urine for low plasma ascorbate concentrations, and that urinary 
ascorbate excretion increases sharply for plasma ascorbate concentrations above 45-60 µmol/L.  
2.3.5.3. Breast milk  
Lactating women secrete vitamin C via breast milk. Vitamin C concentration in human milk reflects 
maternal vitamin C intake more than the infant’s requirement (WHO/FAO, 2004).  
Appendix 4 reports data from seven studies in Europe and the US on the mean vitamin C 
concentration of human milk from healthy lactating mothers not taking vitamin C supplements. Mean 
vitamin C concentration in human milk ranged from 35 to 90 mg/L. Mean maternal vitamin C intake 
reported in six studies ranged from < 80 mg/day to about 150 mg/day; mean plasma concentrations, 
reported in five studies, ranged from 30 to 84 µmol/L. Smoking status was reported in three studies.  
Vitamin C intakes and serum ascorbate concentration were investigated in smoking (n = 16, three of 
them receiving vitamin C supplements) and non-smoking (n = 41, unsupplemented) women during 
their third trimester of pregnancy, and vitamin C concentration in their milk was also investigated. 
While total daily vitamin C intake and serum ascorbate concentration were not statistically different 
between the two groups, women smoking during lactation showed significantly lower vitamin C 
concentrations in both transition and mature milk as compared to non-smoking women (Ortega et al., 
1998a). 
The Panel notes that mean vitamin C concentration of human milk from healthy mothers not taking 
vitamin C supplements is in the range of 35-90 mg/L. 
2.4. Biomarkers 
2.4.1. Biomarkers of intake 
Vitamin C intake can be calculated from food consumption and the vitamin C content of foodstuffs 
available from food composition tables (Deharveng et al., 1999). Plasma ascorbate concentration is not 
a reliable indicator of vitamin C intake since the relationship between vitamin C intake and plasma 
concentration is sigmoidal, i.e. it is approximately linear for low vitamin C intakes but progressively 
reaches a plateau for plasma values above 50 µmol/L (see Section 2.3.2.).  
A systematic review and meta-analysis (Dehghan et al., 2007) investigated the relationship between 
dietary vitamin C intakes, measured by Food Frequency Questionnaire (FFQ), dietary recalls 
(DR)/diary or weight record method (WR), and plasma ascorbate concentrations, from cross-sectional 
or validation studies published between 1960 or 1988 (according to the database considered) and 
2006. Studies were excluded from the review if the dietary intake was not measured quantitatively or 
if the correlation between dietary intake and plasma concentration was not reported. A total of 
26 studies undertaken on 26 631 non-pregnant, non-lactating adults aged 18-65 years including 
smokers (18 740 subjects with DR/diary methods, 6 774 with FFQ and 1 117 with WR) were 
considered, some of which investigated several dietary assessment methods. Mean vitamin C intakes 
ranged between 37 and 327.5 mg/day. Overall, there was a positive linear correlation between plasma 
ascorbate concentration and vitamin C intake either measured by FFQ (crude r = 0.35 for both sexes, 
0.39 for females, and 0.46 for males, 18 studies), or by DR/diary (crude r = 0.46 for both sexes, 0.44 
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for females, and 0.36 for males, ten studies), or by WR (r = 0.39, four studies). The Panel notes that in 
this systematic review, vitamin C intake measured by FFQ, DR/diary or WR had a moderate 
relationship with plasma ascorbate concentration, and that a wide range of vitamin C intakes was 
considered, for which a sigmoidal relationship with plasma ascorbate was observed (Figure 1).  
The Panel considers that plasma ascorbate may be used as a biomarker of vitamin C intake for low 
intakes, i.e. corresponding to the linear part of the sigmoidal curve of plasma ascorbate concentration 
as a function of vitamin C intake. The Panel also considers that for higher intakes and plasma values 
above 50 µmol/L, i.e. at concentrations close to the progressive flattening of the curve, plasma 
ascorbate concentration is of limited value as a biomarker of vitamin C intakes.  
2.4.2. Biomarkers of body stores 
Biomarkers of status are related to the mass balance of vitamin C in the body, which is determined 
from the rate of turnover of the body pool by taking into account metabolic losses, urinary losses and 
the quantity of vitamin C required for the replacement of these losses taking into account its 
absorption efficiency (see Sections 2.3. and 6.1.). 
Plasma and leukocyte ascorbate concentrations are considered appropriate biomarkers of status (IOM, 
2000; Gibson, 2005; Fairweather-Tait, 2011; Levine et al., 2011; EURRECA, online). Plasma 
ascorbate concentration is a valid marker of ascorbate body stores within the usual range of intakes, 
provided that blood samples are taken after an adequate fasting period (Read, 1987; VanderJagt et al., 
1987; Levine et al., 1996). Alternatively, ascorbate concentration in cells such as leukocytes are 
biomarkers of ascorbate body stores independent of recent vitamin C intake. In this Opinion, plasma 
ascorbate, and not leukocyte concentrations, will be used as primary indicator of body stores because 
of the larger number of data available. 
2.4.3. Biomarkers of function 
2.4.3.1. Markers of collagen metabolism  
Vitamin C plays an important role in collagen metabolism. Several biomarkers of in vivo collagen 
metabolism, such as urinary excretion of hydroxyproline (Hevia et al., 1990), have been considered 
(IOM, 2000). Significant changes in markers of collagen turnover can be detected in severe vitamin C 
deficiency. However, markers of collagen turnover are not reliable markers of vitamin C stores and 
cannot be used to identify subjects with subclinical vitamin C deficiency (Hevia et al., 1990; IOM, 
2000). 
The Panel considers that markers of collagen metabolism are not a suitable criterion for deriving the 
requirement for vitamin C.  
2.4.3.2. Markers of carnitine status 
Vitamin C plays an important role in carnitine synthesis (see Section 2.2.3.1.). Carnitine 
concentrations can be measured in urine (Davies et al., 1987; Jacob and Pianalto, 1997) and plasma 
(Johnston et al., 1996). Vitamin C deficiency appears to alter carnitine metabolism, and muscle 
carnitine is depleted in scurvy. However, neither animal nor human studies showed a consistent 
relationship between vitamin C stores and carnitine concentrations (Davies et al., 1987; Rebouche, 
1995; Johnston et al., 1996; Jacob and Pianalto, 1997; IOM, 2000).  
The Panel considers that carnitine concentrations are not a suitable criterion for deriving the 
requirement for vitamin C.  
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2.4.3.3. Markers of oxidative damage 
Vitamin C plays a role in the protection of cells and molecules against oxidative damage. Oxidative 
damage to DNA, proteins and lipids can be measured in vivo using biomarkers validated for that 
purpose (EFSA NDA Panel, 2011).  
Most of the human intervention studies available which have investigated the effects of vitamin C on 
reliable markers of in vivo oxidative damage to molecules have measured plasma or urine isoprostanes 
or isoprostane metabolites to assess oxidative damage to lipids. Few studies or no studies on other 
markers of lipid peroxidation, such as oxidised LDL particles (Van Hoydonck et al., 2004), or on 
markers of oxidative damage to proteins or DNA (Porkkala-Sarataho et al., 2000), are available 
(Heinonen et al., 2012).  
The only depletion–repletion study on in vivo oxidative damage was conducted in hospitalised young 
healthy women, who were depleted with a diet containing < 5 mg/day vitamin C until plasma 
concentrations of ascorbate < 8 µmol/L were achieved with no signs of scurvy. Then, daily doses of 
30-2 500 mg vitamin C were administered in succession until establishment of a new steady state 
under each dose. Plasma and urine F2-isoprostanes, as well as urine concentrations of a major 
metabolite of F2-isoprostanes, were unaffected by vitamin C depletion or vitamin C intake (Levine et 
al., 2001).  
Isoprostanes have been shown to be elevated in chronic conditions associated with increased oxidative 
stress, such as obesity or smoking. A number of randomised, placebo-controlled intervention studies in 
humans have investigated the effects of vitamin C intake on isoprostanes in relation to smoking and 
body weight using supplemental doses of vitamin C between 500 and 1 000 mg/day. Supplementation 
with 500 mg/day vitamin C for two months significantly decreased urinary 8-iso-prostaglandin F2α in 
mostly overweight non-smoking subjects (Huang et al., 2002), and plasma F2-isoprostane 
concentrations in passive smokers (i.e. non-smokers for at least 12 months who had been exposed to 
cigarette smoke of at least one cigarette per day on at least five days/week, indoors) (Dietrich et al., 
2003) and in smokers with a BMI > 26.6 kg/m2, but not in smokers with a BMI < 26.6 kg/m2 (Dietrich 
et al., 2002). Vitamin C supplementation at doses of 1 000 mg/day for two months significantly 
decreased plasma F2-isoprostanes in subjects with elevated values at baseline (Block et al., 2008), 
whereas when given for 17 days it had no effect on urinary or plasma F2-isoprostanes in smoking or 
non-smoking young healthy adults (Kuiper et al., 2011). 
The Panel notes that the studies available suggest an effect of vitamin C supplementation at doses of 
500-1 000 mg/day for two months on total lipid peroxidation in subjects with increased oxidative 
stress as a function of baseline values.  
The Panel also notes that neither subclinical vitamin C deficiency nor subsequent supplementation 
with doses from 30 to 2 500 mg/day appear to affect plasma or urine isoprostanes in healthy subjects, 
and that isoprostanes are not reliable markers of vitamin C stores and cannot be used to identify 
subjects with subclinical vitamin C deficiency. Few data are available on other markers of in vivo 
oxidative damage. 
The Panel considers that markers of in vivo oxidative damage are not a suitable criterion for deriving 
the requirement for vitamin C.  
2.4.3.4. Markers of the function of the immune system 
Leukocytes have a high vitamin C concentration that is known to decline during stress and infection as 
it is used to counteract the oxidative response. Vitamin C has been reported to modulate some markers 
of the function of the immune system such as antimicrobial cell activities, natural killer cell activities, 
lymphocyte proliferation, proinflammatory cytokine production, chemotaxis and delayed dermal 
sensitivity, generally in studies involving healthy subjects supplemented with vitamin C doses 
between 200 mg/day and 6 g/day. However, these markers were not considered as a suitable criterion 
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for deriving the requirement for vitamin C (IOM, 2000). The evidence available to the Panel does not 
establish that modulation of any of these markers is in itself a health outcome which could be 
considered as a suitable criterion for deriving a DRV for vitamin C. 
The Panel considers that markers of the function of the immune system are not a suitable criterion for 
deriving the requirement for vitamin C. 
2.5. Effects of genotype 
Glutathion-S-transferases (GST), which are xenobiotic-metabolising enzymes, and haptoglobin (Hp), 
which is a haemoglobin-binding protein, are characterised by a genetic polymorphism in humans; the 
null genotypes of the GSTM1 and GSTT1 genes lead to the absence of enzyme function (Yuan et al., 
2012) and the Hp2-2 homozygote produces a less active protein (Cahill and El-Sohemy, 2010). 
The Panel notes that plasma/serum ascorbate concentrations may be influenced by these 
polymorphisms, but available data are inconsistent (Langlois et al., 1997; Dusinska et al., 2001; Na et 
al., 2006; Cahill et al., 2009; Cahill and El-Sohemy, 2010; Block et al., 2011; Horska et al., 2011; 
Yuan et al., 2012).  
The Panel considers that data on the effect of genotype on plasma ascorbate concentration are 
insufficient to be used for deriving the requirements for vitamin C according to genotype variants. 
3. Dietary sources and intake data 
3.1. Dietary sources 
Foods with a naturally high vitamin C content are fruits such as berries, lychee, papaya, kiwi, and 
citrus fruits, vegetables like Brussels sprouts, cauliflower, cabbage, sweet pepper, and herbs/spices 
like parsley, sorrel and chives (Anses/CIQUAL, 2012). Animal tissues also contain vitamin C but in 
lower amounts. Kidney and liver have a higher vitamin C content than other animal-derived foods. 
The precise amount of vitamin C in a specific food varies according to season of harvesting, transport, 
shelf time prior to use, and cooking practices. When foods are processed, vitamin C may be exposed to 
oxygen or high temperatures, which accelerate oxidation. Because of its water solubility, vitamin C 
may also be lost when the cooking water is discarded.  
Currently, magnesium L-ascorbate and zinc L-ascorbate may be added to food supplements6, whereas 
L-ascorbic acid, sodium L-ascorbate, calcium L-ascorbate, potassium L-ascorbate, and L-ascorbyl 6-
palmitate may be added to both foods7 and food supplements6. The vitamin C content of infant and 
follow-on formulae is regulated8. 
The main contributors to the vitamin C intake of adults are fruits and vegetables and their juices, and 
potatoes (Serra-Majem et al., 2007; Pedersen et al., 2010; DGE, 2012) (Appendix 1). 
3.2. Dietary intake  
Typical vitamin C intakes of children and adolescents from 20 countries (Appendix 2) and of adults 
from 23 countries (Appendix 3) in Europe are presented. The data refer to individual-based food 
consumption surveys, conducted from 1989 onwards. Most studies comprise nationally representative 
population samples.  
                                                     
6  Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of 
the Member States relating to food supplements, OJ L 183, 12.7.2002, p. 51.  
7  Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of 
vitamins and minerals and of certain other substances to foods, OJ L 404, 30.12.2006, p. 26.  
8  Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending 
Directive 1999/21/EC, OJ L 401, 30.12.2006, p.1. 
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There is a large diversity in the methodology used to assess the individual intakes of children, 
adolescents and adults (Appendices 2A and 3A). These differences in dietary assessment methods 
make comparison difficult. Age classifications may not be uniform and comparability is also hindered 
by differences in the food composition tables used for the conversion of food consumption data to 
nutrient intake data (Deharveng et al., 1999). Dietary intake data are prone to reporting errors and 
there is a varying degree of under-reporting in different surveys (Merten et al., 2011). 
Although the differences in methodologies have an impact on the accuracy of between-country 
comparisons, the data presented give an overview of the vitamin C intake in a number of European 
countries. Most studies reported mean intakes and SD, and sometimes intake distributions. Seven 
surveys out of 43 reported the intakes from both food and dietary supplements.  
In men, average vitamin C intakes from food only range from 69 to 130 mg/day, and in women from 
65 to 138 mg/day. In adults, ranges varied from 11–65 mg/day at the lower end (2.5-25th percentile, 
without dietary supplements) to 106-1 082 mg/day (the value of 1 082 mg/day including dietary 
supplements) at the upper end (75-97.5th percentile) of the intake distributions.  
In infants and young children, average vitamin C intakes from food only range from 44 to 119 mg/day. 
In older children (less than 14 years), average daily vitamin C intakes from food only vary between 60 
and 172 mg/day in boys, and between 61 and 172 mg/day in girls. In adolescents (older than 14 years), 
average vitamin C intakes from food only are between 73 and 146 mg/day in males, and between 75 
and 149 mg/day in females. 
4. Overview of Dietary Reference Values and recommendations 
4.1. Adults 
D-A-CH (2013) stated that epidemiological data showed a reduction in the risk of chronic diseases, in 
particular cardiovascular and cancer morbidity and mortality in non-smokers with plasma ascorbate 
concentrations higher than 50 µmol/L, corresponding to dietary intakes of 90-100 mg/day (Carr AC 
and Frei B, 1999). Another criterion was saturation of immunocompetent cells, achieved with an 
intake of 100 mg/day (Levine et al., 1996; Levine et al., 1997b; Levine et al., 1997a). Using data on 
intakes required to reach plasma ascorbate concentrations of 50-75 µmol/L in male and female non-
smokers (Heseker et al., 1992; Kübler, 1995), and a bioavailability from a mixed diet of at least 80 % 
(Levine et al., 1999), an AR of 82 mg/day and a recommended intake of 100 mg/day were derived for 
adults, considering a coefficient of variation (CV) of 10 %. For heavy smokers (i.e. smoking more 
than 20 cigarettes/day), an intake of 150 mg/day was recommended, considering reduced absorption, 
increased daily turnover and increased oxidative DNA damage in these subjects (Heseker et al., 1992; 
Loft et al., 1992; Asami et al., 1997; Prieme et al., 1998). 
The Nordic countries (NNR, 2012) maintained their lower level of intake at 10 mg/day for adults, as 
well as their previous reference values which were based on the antioxidant activity of vitamin C and 
the association between a plasma ascorbate concentration of 32 µmol/L and a decreased risk of 
cardiovascular or cancer mortality and morbidity (unweighted mean cut-off point for a lowered risk, 
compared to the first quintile of plasma ascorbate, from eight studies) (Riemersma et al., 1991; Gale et 
al., 1995; Singh et al., 1995; Eichholzer et al., 1996; Sahyoun et al., 1996; Nyyssonen et al., 1997; 
Loria et al., 2000; Khaw et al., 2001). Using pharmacokinetic data (Levine et al., 1996; Levine et al., 
2001), this plasma value corresponded to intakes of about 60 mg/day in men and 50 mg/day in 
women, which were set as the ARs. Women were considered to have a slightly lower AR than men 
(Olson and Hodges, 1987), but to ensure adequate iron absorption the allowance for inter-individual 
variation for women was assumed to be double (25 %) that for men, and the same Recommended 
Intake (RI) was thus set for both sexes, i.e. 75 mg/day. Cohort studies on morbidities (Boekholdt et al., 
2006; Harding et al., 2008; Myint et al., 2008; Myint et al., 2011; Pfister et al., 2011) published after 
the last Nordic Nutrition recommendations (NNR, 2004) suggested a higher plasma ascorbate 
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concentration of 40-50 µmol/L as a basis to set the AR, but were considered insufficient to raise the 
AR. No specific recommendation was made for older adults or smokers. 
WHO/FAO (2004) applied the same calculation as SCF (1993) to derive a Recommended Nutrient 
Intake (RNI) of 45 mg/day, considering (i) a body content of 900 mg vitamin C as it is halfway 
between tissue saturation (1 500 mg) and the point at which clinical signs of scurvy appear (300-
400 mg), (ii) an absorption efficiency of 85 % as it is intermediate between absorption observed at low 
dietary doses and that seen in the intake range of 30-180 mg/day (Melethil et al., 1986; Graumlich et 
al., 1997), and (iii) metabolic losses of 2.9 % per day with an SD of 0.6 % (Baker EM et al., 1971). 
Women were considered to have a lower AR than men; however, plasma concentrations fell more 
rapidly in women than in men in depletion studies (Blanchard, 1991b). Thus, the same RNI was 
proposed for adults whatever the sex or age. The AR for vitamin C for adults was interpolated between 
the amount considered to protect against scurvy (10 mg/day) and the RNI of 45 mg/day, i.e. 25-
30 mg/day. It was considered that there was no justification for deriving a specific RNI for smokers. 
Afssa (2001) considered the curve relating the median plasma ascorbate concentrations to increments 
of 25 mg in intake, derived from three 24-hour dietary recalls and one plasma ascorbate determination 
in subjects of a French cohort study (SU.VI.MAX, n = 2 509 women aged 35-60 years and 3 116 men 
aged 40-65 years at inclusion). Plasma concentrations first increased according to intakes, then 
reached steady state values of 64 ± 1 µmol/L in women, and 56 ± 3 µmol/L in men. A sub-group was 
then selected of subjects whose plasma ascorbate concentrations were equal to those values ± 5 %, i.e. 
in the range of 53-59 µmol/L for men (n = 257) and 61-67 µmol/L for women (n = 443). Their 
normalised mean intakes were 85.4 and 85.9 mg/day for men and women, respectively. Adding to 
these values twice a theoretical SD of 15 %, the Population Reference Intake (PRI) was set at 
110 mg/day for both sexes. Considering plasma ascorbate concentrations of subjects from the 
SU.VI.MAX cohort, as well as subjects smoking more than ten cigarettes/day and whose intake 
distribution was similar, Afssa recommended that smokers ingest 20 % more vitamin C per day (i.e. 
130 mg/day). A reference value of 120 mg/day was set for adults aged 75 years and older, based on 
considerations related to supplemental vitamin C intake in older people and immunity, cardiovascular 
risk, cancer risk, and cognition. 
The US Institute of Medicine (IOM, 2000) stated that in order to set requirements, there were no 
human data to derive a dose-response relationship between vitamin C intake and in vivo antioxidant 
protection, but that antioxidant protection and neutrophil ascorbate concentrations are correlated 
(Anderson and Lukey, 1987). Using the limited data on plasma and neutrophil concentrations and 
urinary excretion during vitamin C depletion-repletion in healthy men (Levine et al., 1996), IOM 
selected the value of 80 % of maximal neutrophil ascorbate concentration (i.e. 1 mmol/L), which was 
equivalent to a vitamin C intake of about 75 mg/day considered to be sufficient to maintain near-
maximal neutrophil concentrations with minimal urinary losses, and set this value as the Estimated 
Average Requirement (EAR) for men. Because of the lack of data, the EAR for women (60 mg/day) 
was extrapolated from the value for men, and the quotient between the reference body weight of 
women and that of men (adapted from NHANES III 1988-1994). A Recommended Dietary Allowance 
(RDA) was derived by adding to the EAR twice an assumed CV of 10 % (assumption based on the 
variation in basal metabolic rate and the variation estimated for the protein requirement in adults 
(Garby and Lammert, 1984; FAO/WHO/UNU, 1985)). The RDAs were thus 90 mg/day for men (19-
50 years) and 75 mg/day (rounded value) for women of the same age. No consistent differences in the 
absorption or metabolism of ascorbic acid due to ageing were demonstrated, and therefore the RDA 
set for adults aged more than 50 years was the same as for adults aged less than 50 years. Because of 
higher metabolic losses of vitamin C, smokers were considered to require an additional 35 mg/day of 
vitamin C over that needed by non-smokers (Kallner et al., 1979; Kallner et al., 1981). Passive 
smokers as well as people under excessive physical and emotional stress were also considered, but 
without setting specific values. 
The SCF (1993) considered a total body pool of 900 mg vitamin C (providing reserves for periods of 
low intake or high needs), multiplied by metabolic losses of 2.9 % (Baker EM et al., 1971) (with two 
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SDs of 0.6 % to set the PRI), and divided by an absorption efficiency of 85 %. Thus, an AR of 
30 mg/day and a PRI of 45 mg/day were derived for adults (rounded value). A similar calculation 
targeting the maintenance of a body pool of 600 mg yielded an LTI of 12 mg/day. The PRI for older 
adults was considered to be the same as for younger subjects.  
The Netherlands Food and Nutrition Council (1992) considered that 45 to 60 mg vitamin C/day were 
necessary to maintain the body pool in adults (estimated to be 1 500 mg), and that the requirement 
would thus be between 50 and 65 mg/day considering an absorption efficiency of 80-90 % (Baker et 
al., 1969; Baker EM et al., 1971; Hodges et al., 1971; Kallner et al., 1977, 1979; Kallner et al., 1982). 
Hence, a reference value of 70 mg/day was estimated for adults, assuming an AR of 58 mg/day and 
adding to it a 20 % safety margin for variation, based on depletion-repletion studies (Baker et al., 
1969; Baker EM et al., 1971; Hodges et al., 1971). 
The UK COMA (DH, 1991) focused on the sigmoidal relationship between vitamin C intake and 
plasma ascorbate concentrations (Bates et al., 1979; Basu and Schorah, 1982). Measurable amounts of 
ascorbate were found to begin to circulate in the plasma of most people at an intake of 40 mg/day, 
which was set as the Reference Nutrient Intake for both sexes, and also for older adults because of a 
lack of data. The EAR of 25 mg/day was interpolated between that value and the Lower Reference 
Nutrient Intake (LRNI) of 10 mg/day for adults (based on scurvy prevention). Because of increased 
losses of vitamin C, it was considered that the intake of smokers would need to be higher by up to 
80 mg/day compared to that of non-smokers (Kallner et al., 1981; Smith and Hodges, 1987). 
An overview of Dietary Reference Values for vitamin C for adults from various authorities is given in 
Table 1. In addition, some organisations presented some considerations regarding smokers, and 
proposed for this population an additional daily intake of 35 mg (IOM, 2000), 50 mg (D-A-CH, 2013), 
80 mg (DH, 1991) or 20 % (Afssa, 2001). 
Table 1:  Overview of Dietary Reference Values for vitamin C for adults 
 D-A-CH 
(2013) 
NNR 
(2012) 
WHO/FAO 
(2004) 
Afssa 
(2001) 
IOM 
(2000) 
SCF 
(1993) 
NL 
(1992) 
DH 
(1991) 
Age (years) ≥ 19 ≥ 18 ≥ 19 20-74 ≥ 19 ≥ 18 ≥ 19 ≥ 19 
PRI 
Men (mg/day) 
Women (mg/day) 
 
100 
100 
 
75 
75 
 
45 
45 
 
110 
110 
 
90 
75 
 
45 
45 
 
70 
70 
 
40 
40 
Age (years)    ≥ 75     
PRI 
Men (mg/day) 
Women (mg/day) 
    
120 
120 
   
NL: The Netherlands 
4.2. Infants and children 
D-A-CH (2013) estimated the Adequate Intake (AI) for infants from birth to four months considering 
an average vitamin C concentration in human milk of 65 mg/L (Souci et al., 2008) and an average 
milk intake of 0.75 L/day. The values for older children were interpolated between this AI and the 
reference value for non-smoking adults. 
The Nordic countries (NNR, 2012) extrapolated ARs for children (< 14 years) from adult ARs, using 
an assumed growth factor of 1.3 for children aged less than two years (i.e. reference values of 
20 mg/day for 6-11 months and 25 mg/day for 12-23 months) and a factor of 1.15 for children aged 2-
13 years. The ARs were then multiplied by 1.25 to derive RIs.  
WHO/FAO (2004) concluded that the amount of vitamin C in human milk reflects maternal dietary 
vitamin C intake rather than the infant’s needs. The RNI was set to 25 mg/day for infants from birth to 
six months and increased gradually for older children.  
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For children, Afssa (2001) tested several parameters such as energy expenditure or square height to 
derive values either from the vitamin C intake of breast-fed infants between six months and one year, 
or from the PRI for adults. Estimates from both methods were similar for girls but not for boys, and 
those derived initially for girls were chosen for both sexes considering the lack of difference in 
requirement according to sex in infants and adults. 
For infants aged 7-12 months, the IOM (2000) set an AI of 50 mg/day, considering a vitamin C 
concentration of 45 mg/L in human milk and a milk consumption of 0.6 L/day (Dewey et al., 1984; 
Salmenpera, 1984) corresponding to an intake of 27 mg/day from human milk at nine months of 
lactation, to which an intake of 22 mg/day from solid foods was added (Montalto et al., 1985). An 
alternative method based on extrapolation from the AI for breast-fed infants aged less than six months 
and the quotient between the reference body weights of older and younger infants (adapted from 
NHANES III 1988-1994) provided the same value. For older children, the EARs were estimated from 
those for adults using the quotient between their reference body weights (adapted from NHANES III 
1988-1994). RDAs were derived by adding twice an assumed CV of 10 %, because of the unknown 
SD of the requirement for vitamin C.  
Because of the lack of data, the SCF (1993) set the PRI for infants aged 6-11 months at 20 mg/day, 
mentioning that it corresponds to about three times the intake known to prevent scurvy in infants. The 
PRIs for older children were increased gradually to those for adults.  
The mean intake of vitamin C through human milk was considered as the reference value for infants 
by the Netherlands Food and Nutrition Council (1992) and the UK COMA (DH, 1991), i.e., 
respectively, 35 mg/day (Thomas et al., 1979; Olson and Hodges, 1987) and 25 mg/day (Bates and 
Prentice, 1988). For children, the values were either interpolated between the Dutch reference values 
for infants and for adults, or scaled down from the UK adult values. 
An overview of Dietary Reference Values for vitamin C for children is presented in Table 2. 
Table 2:  Overview of Dietary Reference Values for vitamin C for children 
 D-A-CH 
(2013) 
NNR 
(2012) 
WHO/FAO 
(2004) 
Afssa 
(2001) 
IOM 
(2000) 
SCF 
(1993) 
NL 
(1992) 
DH 
(1991) 
Age (months) 4-< 12 6-11 7-< 12 Infants 7-12 6-11 6-12 6-12 
PRI (mg/day) 55 20 30 50(a) 50(a) 20 35(a) 25(a) 
Age (years) 1-< 4 1-< 2 1-3 1-3 1-3 1-3 1-4 1-3 
PRI (mg/day) 60 25 30 60 15 25 40 30 
Age (years) 4-<7 2-5 4-6 4-6 4-8 4-6 4-7 4-6 
PRI (mg/day) 70 30 30 75 25 25 45 30 
Age (years) 7-< 10 6-9 7-9 7-9 9-13 7-10 7-10 7-10 
PRI (mg/day) 80 40 35 90 45 30 50 30 
Age (years) 10-< 13 10-13 10-18 10-12 14-18 11-14 10-13 11-14 
PRI (mg/day) 90 50 40 100   75 (m) 
65 (f) 
35 55 35 
Age (years) 13-< 19 14-17  13-19  15-17 13-16 15-18 
PRI (mg/day) 100 75  110  40 65 40 
Age (years)       16-18  
PRI (mg/day)         70 (m) 
65 (f) 
 
(a): Adequate Intake 
m, males; f, females; NL: The Netherlands 
4.3. Pregnancy and lactation 
From the fourth month of pregnancy onwards, D-A-CH (2013) added an intake of 10 mg/day to the RI 
for non-pregnant women (hence an RI of 110 mg/day), to help maintain body pools. For lactation,  
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D-A-CH considered a milk production of 0.75 L/day and an average vitamin C content of 65 mg/L, 
and added 50 mg/day to the RI for non-lactating women (i.e. an RI of 150 mg/day). 
The Nordic countries (NNR, 2012) maintained their previous RI of 85 mg/day for pregnancy, i.e. 
higher by 10 mg/day compared to the RI for non-pregnant women, to cover the increased need due to 
the growth of the fetus and the increased catabolism of vitamin C (Olson and Hodges, 1987). During 
lactation, the RI was increased by 25 mg/day to 100 mg/day based on an average vitamin C content of 
30 mg/L in human milk (Olson and Hodges, 1987) and an average milk secretion of 0.75 L/day. 
WHO/FAO (2004) added throughout pregnancy an intake of 10 mg/day to the RNI for non-pregnant 
women (hence an RNI of 55 mg/day) to meet the needs of the growing fetus in the last trimester, as 
8 mg/day is sufficient to prevent signs of scurvy in infants aged four to seven months (Irwin and 
Hutchins, 1976). During lactation, a vitamin C secretion via milk of 20 mg/day and an absorption 
efficiency of 85 % were the basis for recommending an extra 25 mg/day (hence an RNI of 70 mg/day).  
For pregnant women, Afssa (2001) added 10 mg/day to the PRI for non-pregnant women (hence a PRI 
of 120 mg/day) to take into account haemodilution and the active transport of vitamin C through the 
cord and placenta (Morse et al., 1975). For lactating women, Afssa (2001) recommended an additional 
intake of 20-30 mg/day taking into account a vitamin C concentration in human milk of 40-60 mg/L 
(Salmenpera, 1984), and hence a PRI of 130 mg/day. 
IOM (2000) noted that the maternal plasma ascorbate concentration decreases during pregnancy 
because of haemodilution and active transfer to the fetus (Morse et al., 1975; Choi and Rose, 1989), 
but that the amount of vitamin C required for transfer to the fetus was unknown and was estimated 
taking into account that intakes of 7 mg/day prevent scurvy in young infants (Van Eekelen, 1953; 
Goldsmith, 1961; Rajalakshmi et al., 1965). The EAR for near-maximal neutrophil concentration in 
non-pregnant women was therefore increased by 10 mg/day and, after adding twice an assumed CV of 
10 % (because the SD of the requirement for vitamin C was unknown) and rounding, RDAs for 
pregnancy of 80 mg/day (14-18 years) and of 85 mg/day (adult women) were derived. For lactating 
women, the average amount of vitamin C secreted into milk during the first six months of lactation, 
i.e. 40 mg/day, was added to the EAR for non-lactating women. After adding twice an assumed CV of 
10 %, RDAs for lactation of 115 mg/day (14 to 18 years) and 120 mg/day (adult women) were 
derived. 
For pregnant women, the SCF (1993) proposed an additional intake of 10 mg/day to be added to the 
PRI for non-pregnant women to meet the needs of the fetus. For lactating women, an amount of 
20 mg/day of vitamin C was considered to be secreted via milk and, assuming 85 % bioavailability, an 
intake of 25 mg/day was added to the PRI for non-lactating women.  
For pregnant women, the Netherlands Food and Nutrition Council (1992) added 20 mg/day to the 
reference value for non-pregnant women, in agreement with the US National Research Council (NRC, 
1980). For lactating women, the reference value was increased by 40 mg/day compared to non-
lactating women, assuming a bioavailability of 80-90 % and a daily loss of 35 mg of vitamin C via 
milk. 
The UK COMA (DH, 1991) considered that there is a moderate extra drain on tissue stores during 
pregnancy and thus increased the Reference Nutrient Intake by 10 mg/day during the third trimester. 
For lactating women, 30 mg/day were added to the Reference Nutrient Intake for non-lactating women 
to ensure the maintenance of maternal stores and to keep the concentrations in human milk in the 
upper half of the physiological range.  
An overview of Dietary Reference Values for vitamin C for pregnant and lactating women is 
presented in Table 3. 
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Table 3:  Overview of Dietary Reference Values for vitamin C for pregnant and lactating women 
 D-A-CH 
(2013) 
NNR 
(2012)
WHO/ FAO 
(2004) 
Afssa 
(2001)
IOM 
(2000) 
SCF 
(1993) 
NL 
(1992) 
DH 
(1991) 
Pregnancy: 
additional 
intake (mg/day) 
(from 4th month 
onwards) 
  10 
 
 
  10 
 
 
10 
 
 
  10 
 
 
10 
 
 
10 
 
 
  20 
(3rd 
trimester)
10 
PRI (mg/day) 110   85 55 120   80 (14-18 y) 
85 (≥ 19 y) 
55   90 50 
Lactation: 
additional 
intake (mg/day) 
  50   25 25 20-30 40 25   40 30 
PRI (mg/day) 150 100 70 130   115 (14-18 y)
120 (≥ 19 y) 
70 110 70 
NL: The Netherlands; y: years. 
5. Criteria (endpoints) on which to base Dietary Reference Values 
The Panel considers that biomarkers of function for vitamin C, i.e. markers of collagen metabolism, of 
carnitine status, of oxidative damage, or of function of the immune system, cannot be used as a 
criterion for deriving the requirement for vitamin C. Other markers or outcomes may be considered for 
deriving this requirement. 
5.1. Scurvy 
Scurvy can be prevented by a vitamin C intake above 10 mg/day (see Section 2.2.3.1.). The Panel 
concludes that this low amount represents the intake associated with the appearance of severe 
deficiency but cannot be used as a criterion for deriving the requirement for vitamin C. 
5.2. Biomarkers of body stores 
The maintenance of the body pool and plasma and cellular concentrations of vitamin C can be 
considered as a criterion for establishing the requirement for vitamin C, assuming that body pools and 
plasma concentrations near saturation are associated with fulfilling vitamin C’s coenzymatic and 
antioxidant functions.  
Plasma ascorbate concentration is considered in this Opinion as the primary indicator of body stores 
(see Section 2). Plasma ascorbate concentration < 10 µmol/L is regarded as indicative of severe 
deficiency, and in the range from 10 to < 50 µmol/L as indicative of suboptimal status with a risk of 
insufficiency. A plasma concentration of 45-50 µmol/L was shown to correspond to the saturation of 
the pathways involved in the metabolic losses of ascorbic acid, and may represent the amount of 
ascorbic acid required to exert its physiological role (Kallner et al., 1979). A plasma ascorbate 
concentration of 50 µmol/L is indicative of adequate status that corresponds to a body pool of about 
1.5 g with metabolic losses of about 3.0 % per day (or 40-50 mg/day). No additional increase in 
muscle ascorbate concentration was observed in non-smoking men at a plasma ascorbate concentration 
above around 50 µmol/L (Carr et al., 2013). 
Ascorbate is excreted in urine even for low plasma ascorbate concentrations. For plasma 
concentrations above around 50 µmol/L, urinary ascorbate excretion increases sharply, and this is 
assumed to reflect near-saturation of body pools.  
In healthy male adults, a plasma ascorbate concentration of 50 µmol/L is reached with a vitamin C 
intake between 60 and 100 mg/day, with intestinal losses of about 20 % and urinary excretion up to 
25 % of the intake. Vitamin C intakes above 200 mg/day progressively elevate the plasma 
concentration to a plateau of 70-80 µmol/L or even above, at the expense of a dramatic increase in 
urinary excretion. Women reach a plasma ascorbate concentration of 50 µmol/L with a slightly lower 
intake of vitamin C compared to men.  
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The pharmacokinetics of vitamin C were compared in young and elderly men and women following a 
500 mg oral dose administered to each subject either in a depleted state achieved by four to five weeks 
on a diet containing less than 10 mg vitamin C/day, or in a repleted state achieved following daily 
vitamin C doses of 500 mg/day for the three following weeks (Blanchard, 1991a). Men were taller and 
heavier than women and consequently had a greater body surface area. In the repleted state, compared 
to men, women exhibited a significantly greater peak plasma ascorbate concentration (Cmax), a 
shorter absorption lag time (tlag), as well as greater apparent volume of distribution (AVd), clearance 
(CL) and renal clearance (CLr) when these were expressed relative to body weight. However, when 
AVd, CL and CLr were expressed in absolute terms (i.e. L or mL/min), no sex-related differences 
were observed. In addition, Cmax was inversely linearly related to body weight, tlag was directly 
related to body surface area and dose, and AVd (L/kg) was inversely linearly related to body surface 
area, while CL (mL/h per kg) and CLr (mL/h per kg) were not significantly related to any of the body 
composition parameters examined (e.g. body weight, body surface area and body composition). The 
Panel notes that this study shows few sex-related differences in the pharmacokinetics of vitamin C, 
and that they may be related to differences in body weight and body surface area between the sexes 
(Blanchard, 1991a).  
The Panel also notes that women reach the plateau of plasma ascorbate concentration at a lower 
vitamin C intake than men, but that the value of the plasma concentration at the plateau is similar in 
women and men (Levine et al., 1996; Levine et al., 2001; Levine et al., 2011) (see Section 2.3.2.). 
In smokers, the plasma ascorbate concentration is usually lower than in non-smokers because of 
higher metabolic losses of vitamin C compared to non-smokers at similar vitamin C intakes. 
IOM (2000) concluded from the available evidence that there were no consistent differences in the 
measurements of intestinal absorption, urinary excretion or plasma and leukocyte concentrations of 
ascorbate in older compared to younger adults. The Panel notes that no new data on the influence of 
ageing on these parameters have become available since then.  
The Panel considers that in healthy adults, an intake of vitamin C that balances daily losses and 
maintains a plasma concentration of 50 µmol/L, corresponding to near-saturation of body pools with 
minimal urinary excretion, allows the fulfillment of the functions of vitamin C, and is a suitable 
criterion for deriving the requirement for vitamin C. 
5.3. Markers of disease risk 
5.3.1. Blood lipids 
Randomised controlled trials (RCTs) on the effects of vitamin C at doses of 1 000 mg/day for eight 
months in healthy subjects showed no effect on blood lipids (Jacques et al., 1995; Jenner et al., 2000), 
whereas the same dose administered for four weeks decreased plasma LDL-cholesterol concentration 
by 16 % in healthy women (Gatto et al., 1996). No studies are available at lower doses.  
The Panel considers that the data provided by these studies on blood lipids cannot be used as a 
criterion for deriving the requirement for vitamin C.  
5.3.2. Blood pressure 
A prospective cohort study using the European Prospective Investigation into Cancer and Nutrition 
(EPIC) Norfolk cohort assessed the relationship between plasma concentrations of ascorbate at 
baseline and incident heart failure during a mean follow-up of about 12 years (20 299 participants). 
After adjusting for relevant confounders every 20 μmol/L difference in plasma, vitamin C was 
significantly associated with - 0.9 mmHg systolic blood pressure (SBP) and - 0.5 mmHg diastolic 
blood pressure (DBP). The risk of having high SBP in the fourth quartile of plasma ascorbate 
concentrations (≥ 66 μmol/L) was 22 % lower (odds ratio: 0.78, 95% CI 0.71-0.86) than in the first 
quartile (< 41 μmol/L) (Pfister et al., 2011).  
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The effect of vitamin C supplementation on blood pressure was evaluated in a meta-analysis of 
29 RCTs (Juraschek et al., 2012). Doses of vitamin C ranged from 60 to 4 000 mg/day (median 
500 mg/day), interventions lasted two to 26 weeks (median eight weeks) and trial size ranged from ten 
to 120 subjects. Fifteen trials permitted concurrent use of antihypertensive agents. Sixteen trials used 
vitamin C alone in their intervention arms, whereas 13 trials used a combination of vitamins and 
minerals that included vitamin C. Pre-treatment plasma ascorbate concentrations ranged from 38 to 
83 µmol/L. There was a large heterogeneity across studies and greater reductions in SBP were 
observed in trials which administered vitamin C in combination with vitamins, minerals and blood 
pressure-lowering medications. Vitamin C supplementation when used alone significantly reduced 
SBP but not DBP. Sensitivity analyses showed that the effect on blood pressure did not depend on the 
dose of vitamin C administered or on plasma ascorbate concentrations at baseline, but rather on 
sample size and the accuracy of blood pressure measurements.  
The Panel considers that the data provided by these studies on blood pressure cannot be used as a 
criterion for deriving the requirement for vitamin C.  
5.4. Common cold 
A number of human studies have addressed the relationship between the intake of high doses of 
vitamin C (generally > 500 mg/day) and the risk, severity and duration of common cold. Available 
evidence concerning doses up to 2 000 mg/day was not consistent or specific enough to estimate the 
vitamin C requirement based on this outcome, as previously discussed by IOM (2000).  
A recent meta-analysis of randomised placebo-controlled trials (Hemila and Chalker, 2013) 
investigated the effect of vitamin C supplementation (> 200 mg/day) on common cold. Primary 
outcomes were the incidence and duration of common cold. Regular vitamin C supplementation did 
not reduce significantly the incidence of common cold in the general population (pooled risk ratio 
from 24 trials involving 10 708 participants: 0.97; 95 % CI 0.94-1.00). The pooled effect of vitamin C 
supplementation on the duration of common cold was a 14.2 % (95 % CI 7.3 %-21 %) reduction in 
children (14 trials), and a 7.7 % (95 % CI 3.7 %-12 %) reduction in adults (17 trials). The majority of 
trials used 1 g/day of vitamin C. Sensitivity analyses excluding non-randomised or not-double-blind 
trials did not change the estimates. The Panel notes that common colds were self-diagnosed in the 
majority of trials, and that no clear criteria were specified in the meta-analysis to assess either the 
severity or the duration of a common cold episode.  
The Panel considers that the data available on common cold-related outcomes cannot be used as a 
criterion for deriving the requirement for vitamin C. 
5.5. Chronic disease-related outcomes 
Oxidative damage to cells and molecules has been implicated in the development of a number of 
chronic diseases. Because of its antioxidant role in the body, it has been hypothesised that vitamin C 
could affect the incidence, morbidity and/or mortality of such diseases. 
The relationship between vitamin C intakes and/or body stores and chronic disease outcomes has been 
investigated mostly in observational (case-control, cross-sectional, prospective cohort) studies, where 
a positive, an inverse, or a lack of an association between vitamin C and disease outcomes might be 
counfounded by uncertainties inherent to the methodology used for the assessment of vitamin C 
intakes and/or vitamin C stores, and by the effect of other dietary, lifestyle, or undefined factors on the 
disease outcomes investigated.  
IOM (2000) reviewed the evidence available in relation to vitamin C intakes and risk of cardiovascular 
diseases, cancers, cataracts, chronic obstructive pulmonary disease, infectious diseases, cognitive 
function and memory. Several, but not all, observational studies had reported an inverse correlation 
between vitamin C intakes and cardiovascular disease, some types of cancer and cataracts, whereas no 
evidence was found for an association between vitamin C intakes and the remaining disease outcomes. 
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Although useful in the generation of hypotheses about the role of vitamin C in chronic disease 
development, the results from these studies were not consistent or specific enough to derive a 
requirement for vitamin C. 
A comprehensive search of the literature published between 1991 and 2011 was performed as 
preparatory work to this assessment, to identify relevant health outcomes upon which DRVs for 
vitamin C may potentially be based (Heinonen et al., 2012). Inconsistent associations between 
vitamin C intakes and/or plasma concentrations of ascorbate and risk of diabetes, bone mineral 
density, Parkinson’s disease, Alzheimer’s disease, dementia, preterm delivery, wheeze and eczema in 
the first two years of life, medulloblastoma during childhood, hearing loss, periodontal disease, and 
multiple sclerosis, among others, have been reported. The low number of studies available for each of 
these outcomes does not allow conclusions to be drawn on a putative role of vitamin C in the 
pathogenesis of these conditions. 
More data have become available on the relationship between vitamin C intake and the risk of 
cardiovascular diseases, cancer and vision-related outcomes and mortality.  
5.5.1. Cardiovascular disease-related outcomes 
Results from epidemiological studies on the relationship between vitamin C intake or status and 
cardiovascular disease (CVD) risk are heterogeneous and difficult to compare because of the diversity 
of outcome measures assessed.  
A prospective cohort study from the EPIC Norfolk cohort (Pfister et al., 2011) assessed the 
relationship between plasma concentrations of ascorbate at baseline and incident heart failure (either 
treatment for the disease or death from the disease) during a mean follow-up of 12.8 years 
(20 926 participants). After adjusting for relevant confounders, including myocardial infarction (MI) 
and ischemic heart disease, every 20 μmol/L difference in plasma ascorbate concentration was 
associated with an 8 % (95 % CI 2 %-13 %, P = 0.01) lower risk of incident heart failure. Excluding 
cases diagnosed in the first two years of follow-up did not change the results. The association was 
stronger in subjects who ever smoked (about 65 % in men and 42 % in women) and in subjects with 
hypertension.  
Three prospective cohort studies and one case-control study investigated the association between 
vitamin C intakes and different CVD-related outcomes. The case (n = 108)-control (n = 142) study 
(Nam et al., 2003) reported significantly less cases of non-fatal ischaemic heart disease (MI or 
coronary stenosis ≥ 50 %) in the highest tertile of vitamin C intake (≥ 220.2 mg/day) compared with 
the lowest tertile (< 141.8 mg/day) in a population of which about 55 % were smokers, after 
adjustment for relevant confounders. The association remained significant after exclusion of subjects 
taking multivitamins or vitamin C supplements. In a prospective cohort study (Osganian et al., 2003) 
including 85 118 female nurses and with a follow-up of 16 years, an inverse association between 
vitamin C intakes from food and supplements combined (energy-adjusted mean about 300 mg/day, 
lowest to highest quintiles about 70-700 mg/day) and risk of incident CHD (non-fatal MI, fatal CHD 
and sudden death of probable coronary origin) was observed, whereas the association between dietary 
vitamin C intake and incident CHD was not significant in non-supplement users. The remaining 
prospective cohort studies did not find a significant association between vitamin C intakes and other 
CVD-related outcomes, such as CVD mortality (ischemic heart disease and stroke; 559 men followed-
up for 15 years) (Buijsse et al., 2008) or death from stroke (34 492 postmenopausal women; mean 
duration of follow-up not reported) (Yochum et al., 2000).  
The only large RCT available on vitamin C supplementation (500 mg/day) and cardiovascular 
morbidity and mortality was conducted in 14 641 male physicians, including 5.1 % with prevalent 
cardiovascular disease at randomisation. No effect of supplementation was observed during a mean 
follow-up of eight years (Sesso et al., 2008). 
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5.5.2. Cancer 
The World Cancer Research Fund (WCRF) (2007) found insufficient evidence for an association 
between vitamin C and cancers of the mouth, pharynx, larynx, lung, stomach, pancreas, gallbladder, 
colon, rectum, breast, ovary, endometrium, prostate, kidney, bladder and skin. An inverse association 
was reported with oesophageal cancer, which was based on significant inverse associations in 10 out 
of 18 case-control studies but in none of the other studies considered (one cohort and three cross-
sectional studies). Not all available studies addressed the relationship between this outcome and 
vitamin C intakes, but rather assessed the relationship with certain food groups. 
Studies published after the WCRF report include two cohort studies showing no association between 
dietary and/or total vitamin C intake and breast cancer risk in premenopausal and postmenopausal 
women (Nagel et al., 2010; Hutchinson et al., 2012), a nested case-control study showing no 
association between vitamin C intake and gastric cancer risk (Jenab et al., 2006), a case-control study 
showing no association between vitamin C intake and risk of renal cell carcinoma (Hu et al., 2009), a 
nested case-control study showing no association between vitamin C intake or plasma ascorbate 
concentrations and urothelial cell carcinoma (Ros et al., 2012), a controlled trial showing no effect of 
vitamin C on colorectum, lung and other cancers (Gaziano et al., 2009), a meta-analysis of RCTs 
reporting no effect of vitamin C intakes on incidence and mortality from prostate cancer (Jiang et al., 
2010), and a prospective cohort study showing no effect of total, dietary and supplemental intake of 
vitamin C on prostate cancer (Roswall et al., 2013).  
5.5.3. Vision-related outcomes 
In the IOM report, three case-control comparisons (Robertson et al., 1989; Jacques and Chylack, 1991; 
Leske et al., 1991) were described that showed an association between high vitamin C intakes or 
vitamin C supplement use and a decreased risk for cataract. An inverse association was also found in a 
prospective cohort study for long-term users of vitamin C supplements only (Hankinson et al., 1992), 
but not in another cohort study (Vitale et al., 1993). One cohort study published after the IOM report 
indicated that the use of vitamin C supplements may be associated with a higher risk of age-related 
cataract (hazard ratio 1.25; 95 % CI 1.05-1.50) in women followed up for 8.2 years and compared to 
non-users of vitamin C supplements (Rautiainen et al., 2010). A systematic search and meta-analysis 
of observational studies on the relationship between plasma ascorbate concentration and risk of age-
related cataract showed that plasma ascorbate was inversely associated with age-related cataract in 
Asian (OR: 0.67; 95% CI: 0.57, 0.78, two studies) but not in Western (OR: 0.73; 95 % CI: 0.49, 1.08, 
five studies) populations (Cui et al., 2013).  
Studies addressing other vision-related outcomes in predominantly middle-aged or older subjects have 
not found an association between vitamin C intake and open-angle glaucoma (one large cohort study, 
(Kang et al., 2003)), age-related maculopathy (two cross-sectional studies, (Smith et al., 1999; 
O'Connell et al., 2008)), and age-related macular degeneration (one case-control study, (Seddon et al., 
1994)). 
5.5.4. Mortality 
No effect of vitamin C intake on total mortality was observed in a systematic review, with meta-
analysis, of randomised trials investigating the relationship between supplements of beta-carotene, 
vitamins A, C and E, and selenium, either alone or in combination, on overall mortality (Bjelakovic et 
al., 2007), as well as in a randomised, double-blind, placebo-controlled, 2 x 2 x 2 x 2 factorial trial of 
male US physicians (receiving a multivitamin supplement or its placebo daily, vitamin E (400 IU) or 
its placebo on alternate days, vitamin C (500 mg) or its placebo daily, and beta-carotene (50 mg) or its 
placebo on alternate days) (Gaziano et al., 2009).  
5.5.5. Conclusions on chronic disease-related outcomes 
The Panel considers that the data available on vitamin C intake or status and cardiovascular disease-
related outcomes and vision-related outcomes are not consistent or specific enough, and cannot be 
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used as a criterion for deriving the requirement for vitamin C. The Panel considers that there is no 
association between vitamin C intake and cancer-related outcomes or total mortality, and that available 
data on such outcomes cannot be used as a criterion for deriving the requirement for vitamin C. 
5.6. Specific requirements during pregnancy and lactation 
For pregnant women, haemodilution and active transfer of vitamin C to the fetus produce a decrease in 
maternal plasma ascorbate concentration inducing an additional need for vitamin C. The Panel notes 
that based on this, IOM (2000) added 10 mg/day to the EAR of non-pregnant women, while other 
authorities such as WHO/FAO (2004) recommended that the same value of 10 mg/day be added to the 
PRI or the value equivalent to the PRI (see Section 4.3.).  
From the seven available studies (see Appendix 4 and Section 2.3.5.3.), mean milk vitamin C 
concentrations are in the range of 35-90 mg/L for mean maternal vitamin C intakes and mean maternal 
plasma concentrations, when reported, ranging from < 80 mg/day to 150 mg/day and from 30.1 to 
84.1 µmol/L, respectively. However, two studies (Salmenpera, 1984; Daneel-Otterbech et al., 2005) 
made use of large samples (n = 142 and 200, respectively), providing data that had a relatively small 
SD (suggesting a normal distribution) and that were collected in Europe (Switzerland and Finland, 
respectively). Mean vitamin C concentration in breast milk in these two studies ranged from about 
40 to 60 mg/L, with a midpoint at 50 mg/L. For women exclusively breastfeeding, the mean milk 
transfer over the first six months post partum is assumed to be 0.8 L/day (Butte et al., 2002; 
FAO/WHO/UNU, 2004; EFSA NDA Panel, 2009). From these values, the Panel notes that an average 
quantity of 40 mg/day of vitamin C is estimated to be secreted with milk. 
6. Data on which to base Dietary Reference Values 
Taking into account the available data on the relationship between vitamin C intake and its status, 
functions, and health effects, the Panel considers the maintenance of vitamin C status and total body 
pool as the most suitable criterion for deriving ARs for vitamin C. In the absence of knowledge about 
the variation in requirement, and taking into account the agreement between studies used for further 
calculations, the Panel considered a CV of 10 % to be justified. In addition, rounding to the closest 5 
for ARs and PRIs is chosen as a general rule. 
6.1. Adults 
The Panel decided to determine the AR for vitamin C in healthy adults from the quantity of vitamin C 
that balances metabolic vitamin C losses and maintains fasting plasma ascorbate concentrations at 
about 50 µmol/L. The latter is considered by the Panel as indicative of an adequate vitamin C status 
(or vitamin C body pool) at which the different functions of vitamin C in the body can be fulfilled. 
Taking a conservative approach, and based on the fact that a complete set of data was only available in 
men (see Sections 2.3. and 5.2.), the Panel selected metabolic losses of 50 mg/day, an absorption of 
80 % and a urinary excretion of 25 % of the vitamin C intake. From these values, the mean daily 
vitamin C intake required to balance daily losses in men can be calculated using the following 
formula:  
AR[mg/day] = metabolic losses[mg/day]/((absorption[percentage of intake] – urinary excretion[percentage of intake])/100) 
According to this formula, a mean intake of 91 mg/day of vitamin C (rounded to 90 mg/day in 
Table 4) is required to balance daily losses. The Panel considers that this amount represents the AR, 
and assuming a CV of 10 %, a PRI of 110 mg/day of vitamin C is derived for men. This intake is 
associated with a plasma ascorbate concentration above 50 µmol/L in almost all subjects of the 
population of healthy men. 
Women reach the plateau of plasma ascorbate concentration at a lower vitamin C intake than men, but 
the value of the plasma concentration at the plateau is similar in women and men (see Section 2.3.2.). 
As no values for metabolic losses are available in women, the AR for women is extrapolated from the 
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AR for men. This is done by isometric scaling (linear with body weight), since vitamin C is considered 
to be distributed throughout the whole body, since the multi-compartment models used to calculate the 
metabolic losses in men consider an exchange with only one whole body tissue pool, since few sex-
related differences could be observed in the pharmacokinetics of vitamin C, and since a main part of 
the observed differences can be explained by body weight differences between sexes:  
ARwomen = ARmen (body weight of women/body weight of men).  
Thus, the Panel considers a value of 78 mg/day as the AR for vitamin C for women (rounded to 
80 mg/day in Table 4). Assuming a CV of 10 %, and rounding to the closest 5, a PRI of 95 mg/day of 
vitamin C is derived for women. 
Because of a scarcity of data on the influence of ageing, the Panel concludes that there are insufficient 
data to derive different DRVs for vitamin C for older adults compared to younger adults.  
Table 4:  Reference body weights, Average Requirements (ARs) and Population Reference Intakes 
(PRIs) of vitamin C for men and women 
Reference body weight(a) (kg) AR (mg/day) PRI (mg/day) 
Men Women Men Women Men Women 
68.1  58.5 90 80 110 95 
(a):  Median body weight of 18 to 79-year-old men and women, respectively, based on measured body heights of 16 500 men 
and 19 969 women in 13 EU Member States and assuming a BMI of 22 kg/m2 (see Appendix 11 in EFSA NDA Panel 
(2013)).  
Values for ARs and PRIs were rounded to the closest 5, but PRIs were calculated based on the unrounded ARs. 
6.2. Infants 
The Panel considers that there are no new data to set an AR and thus a PRI for infants aged  
7-11 months. The adequate intake (AI) resulting from observed intakes of breastfed infants is likely 
much higher than the requirement. Because foods consumed by infants in the second half year of life 
are often fortified with vitamin C, it was not considered suitable to use observed intakes as a basis for 
setting an adequate intake. The SCF (1993) set the PRI for infants aged 6-11 months at 20 mg/day. 
The Panel therefore retains this reference value for infants aged 7-11 months. 
6.3. Children and adolescents 
For children and adolescents, the Panel considers that there is no available data obtained in children 
that can be used to set the AR, thus the AR for vitamin C is extrapolated from the AR for adults taking 
into account differences in reference body weight (isometric scaling):  
ARchild = ARadult (body weight of child/body weight of adult). 
There are no data indicating that specific categories of age should be considered for vitamin C 
requirement for children and adolescents. As a consequence, the age categories as proposed in EFSA 
NDA Panel (2010) are applied for children and adolescents.  
Assuming a CV of 10 %, and rounding to the nearest 5, the Panel derives the following PRIs 
(Table 5). 
Dietary Reference Values for vitamin C
 
EFSA Journal 2013;11(11):3418 32
Table 5:  Reference body weights, Average Requirements (ARs) and Population Reference Intakes 
(PRIs) of vitamin C for children and adolescents  
Age Reference body weight (kg) AR (mg/day)(f) PRI (mg/day)(g) 
 Boys Girls Boys Girls Boys Girls 
  1-3 years 12.2(a) 11.5(a) 15 15   20 20 
  4-6 years 19.2(b) 18.7(b) 25 25   30 30 
  7-10 years 29.0(c) 28.4(c) 40 40   45 45 
11-14 years 44.0(d) 45.1(d) 60 60   70 70 
15-17 years 64.1(e) 56.4(e) 85 75 100 90 
(a):  Median body weight-for-age of boys or girls, respectively, aged 24 months (WHO Multicentre Growth Reference Study 
Group, 2006). 
(b): Median body weight of boys or girls, respectively, aged 5 years (van Buuren et al., 2012). 
(c): Median body weight of boys or girls, respectively, aged 8.5 years (van Buuren et al., 2012).. 
(d): Median body weight of boys or girls, respectively, aged 12.5 years (van Buuren et al., 2012).. 
(e): Median body weight of boys or girls, respectively, aged 16 years (van Buuren et al., 2012).. 
(f): ARs derived from the unrounded ARs for adults after adjustment on the basis of differences in reference weight, then 
rounded to the closest 5. 
(g): PRIs derived from the unrounded ARs assuming a CV of 10 %, and then rounded to the closest 5. 
6.4. Pregnancy and lactation 
For pregnant women, in agreement with the value and approach of WHO/FAO (2004), which has also 
been endorsed by other expert Committees, and even though the scientific basis for this additional 
intake is limited, the Panel proposes an intake of 10 mg/day in addition to the PRI for non-pregnant 
women. This is compatible with the previous considerations that vitamin C is considered to be 
distributed in one whole body compartment. 
For lactating women, an additional intake of vitamin C is necessary to balance vitamin C losses in 
human milk. An average quantity of 40 mg/day of vitamin C is estimated to be secreted with milk over 
the first six months post partum (see Section 5.6.). Assuming an absorption efficiency of vitamin C of 
80 %, a mean vitamin C intake of 50 mg/day is required to balance the amount of vitamin C secreted 
in milk for exclusively breastfeeding women during the first six months of lactation, in addition to the 
AR of non-lactating women. Assuming a CV of 10 %, an additional intake of 60 mg/day is derived for 
exclusively breastfeeding women, in addition to the PRI for non-lactating women. 
CONCLUSIONS 
The Panel concludes that an Average Requirement (AR) and a Population Reference Intake (PRI) for 
vitamin C can be derived for adults and children based on vitamin C status, and for pregnant and 
lactating women based on estimation of additional needs and factorial calculation of losses in breast 
milk, respectively.  
For infants aged 7-11 months, the Panel retains the PRI set by the SCF (1993), i.e. 20 mg/day, as no 
suitable evidence has emerged since the previous assessment. 
The Panel also considered several health outcomes that may be associated with vitamin C intake; 
however, the available data were considered insufficient for the setting of DRVs.  
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Table 6:  Summary of Dietary Reference Values for vitamin C 
 PRI (mg/day) 
Age Males Females 
  7-11 months   20     20 
  1-3 years   20     20 
  4-6 years   30     30 
7-10 years   45     45 
11-14 years   70     70 
15-17 years 100      90 
≥ 18 years 110      95 
Pregnancy - + 10 
Lactation - + 60 
RECOMMENDATIONS FOR RESEARCH  
Information related to the body pool of vitamin C is limited and the Panel suggests the development of 
methods for its precise measurement including isotope dilution methods in order to determine its size 
and variation. Relatively few data are available on the turnover of the body pool of vitamin C, and on 
metabolic and urinary losses, and the Panel proposes that methods for their estimation should be 
developed, taking into account different factors such as age (in children and adults), sex and smoking.  
Future studies should also address the suitability of various biomarkers of status (such as plasma 
ascorbate vs leukocyte ascorbate) as best indicator of the requirement. The influence of genotype on 
plasma ascorbate concentration may also require future research.  
The understanding of vitamin C’s antioxidant activity, and of its potential protective effects on tissues 
and different health outcomes, may also require further research, as well as whether a vitamin C intake 
beyond the PRI affects relevant biomarkers of oxidative damage to lipids, DNA and proteins in 
intervention studies, including an assessment of dose-response relationship where relevant.  
The Panel also suggests obtaining data in infants and children on vitamin C intakes in relation to 
plasma ascorbate concentrations, and collecting data on vitamin C intakes of European infants aged  
7-11 months, distinguishing between fortified and non-fortified foods, and types of milk intake (breast 
milk, infant formula, cow’s milk). 
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APPENDICES 
Appendix 1. Foods contributing to vitamin C intake in Denmark, Spain and Germany 
 
Adapted from Pedersen et al. (2010) (children and adults) 
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Appendix 2A. Population, methods and period of dietary assessment in children and adolescents in European countries 
Country Population Dietary assessment method Year of 
survey 
Reference 
Austria Boys and girls aged   7-9 years Three-day record 2007-2008 (Elmadfa et al., 2009a; Elmadfa et al., 2009b) 
 Boys and girls aged 10-14 years Three-day record 2007-2008 (Elmadfa et al., 2009a; Elmadfa et al., 2009b) 
 Boys and girls aged 14-19 years 24-hour recall 2003-2004 (Elmadfa et al., 2009a; Elmadfa et al., 2009b). Mainly from a large Viennese sample. 
     
Belgium Boys and girls aged  2.5-3 years Three -day record 2002-2003 (Huybrechts and De Henauw, 2007). Data collected in Flanders. 
 Boys and girls aged  4-6.5 years Three -day record 2002-2003 (Huybrechts and De Henauw, 2007). Data collected in Flanders. 
 Boys and girls aged 15-18 years Two non consecutive 24-hour recall 2004 (De Vriese et al., 2006) 
     
Bulgaria Boys and girls aged   1-3 years 24-hour recall 1998 (Abrasheva et al., 1998) 
 Boys and girls aged   3-6 years 24-hour recall 1998 (Abrasheva et al., 1998) 
 Boys and girls aged   6-10 years 24-hour recall 1998 (Abrasheva et al., 1998) 
 Boys and girls aged 10-14 years 24-hour recall 1998 (Abrasheva et al., 1998) 
 Boys and girls aged 14-18 years 24-hour recall 1998 (Abrasheva et al., 1998) 
     
Czech  Boys and girls aged 4-6 years 48-hour recall 2007 (Elmadfa et al., 2009b) 
Republic Boys and girls aged 7-9 years 48-hour recall 2007 (Elmadfa et al., 2009b) 
     
Denmark Boys and girls aged   1-3 years Seven-day record 1995 (Andersen et al., 1996) 
 Boys and girls aged   4-5 years Seven-day record 2003-2008 (Pedersen et al., 2010) 
 Boys and girls aged   6-9 years Seven-day record 2003-2008 (Pedersen et al., 2010) 
 Boys and girls aged 10-13 years Seven-day record 2003-2008 (Pedersen et al., 2010) 
 Boys and girls aged 14-17 years Seven-day record 2003-2008 (Pedersen et al., 2010) 
     
Finland Children aged 1 year Three-day record 2003-2005 (Kyttälä et al., 2008; Kyttälä et al., 2010) 
 Children aged 2 years Three-day record 2003-2005 (Kyttälä et al., 2008; Kyttälä et al., 2010) 
 Children aged 3 years Three-day record 2003-2005 (Kyttälä et al., 2008; Kyttälä et al., 2010) 
 Children aged 4 years Three-day record 2003-2005 (Kyttälä et al., 2008; Kyttälä et al., 2010) 
 Children aged 6 years Three-day record 2003-2005 (Kyttälä et al., 2008; Kyttälä et al., 2010) 
     
France Boys and girls aged   1-3 mo Consecutive 3-day record 2005 (Fantino and Gourmet, 2008) 
 Boys and girls aged   4 mo Consecutive 3-day record 2005 (Fantino and Gourmet, 2008) 
 Boys and girls aged   5 mo Consecutive 3-day record 2005 (Fantino and Gourmet, 2008) 
 Boys and girls aged   6 mo Consecutive 3-day record 2005 (Fantino and Gourmet, 2008) 
 Boys and girls aged   7 mo Consecutive 3-day record 2005 (Fantino and Gourmet, 2008) 
 Boys and girls aged   8-9 mo Consecutive 3-day record 2005 (Fantino and Gourmet, 2008) 
 Boys and girls aged 10-12 mo Consecutive 3-day record 2005 (Fantino and Gourmet, 2008) 
 Boys and girls aged 13-18 mo Consecutive 3-day record 2005 (Fantino and Gourmet, 2008) 
 Boys and girls aged 19-24 mo Consecutive 3-day record 2005 (Fantino and Gourmet, 2008) 
 Boys and girls aged 25-30 mo Consecutive 3-day record 2005 (Fantino and Gourmet, 2008) 
 Boys and girls aged 31-36 mo Consecutive 3-day record 2005 (Fantino and Gourmet, 2008) 
 Boys and girls aged   3-10 years Seven-day record 2006-2007 (Afssa, 2009) 
 Boys and girls aged 11-14 years Seven-day record 2006-2007 (Afssa, 2009) 
 Boys and girls aged 15-17 years Seven-day record 2006-2007 (Afssa, 2009) 
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Country Population Dietary assessment method Year of 
survey 
Reference 
     
Germany Boys and girls aged   6 years Three-day record 2006 (Mensink et al., 2007; Elmadfa et al., 2009b) 
 Boys and girls aged   7-9 years Three-day record 2006 (Mensink et al., 2007; Elmadfa et al., 2009b) 
 Boys and girls aged 10-11 years Three-day record 2006 (Mensink et al., 2007; Elmadfa et al., 2009b) 
 Boys and girls aged 12 years Dietary history (over the last four weeks) 2006 (Mensink et al., 2007; Elmadfa et al., 2009b) 
 Boys and girls aged 13-14 years Dietary history (over the last four weeks) 2006 (Mensink et al., 2007; Elmadfa et al., 2009b) 
 Boys and girls aged 14-18 years Two non-consecutive 24-hour dietary recalls  2005-2006 (DGE, 2012) 
     
Greece Boys and girls aged 1-5 years  Three-day record (weighed food records and 24-hour recall or 
food diaries) 
2003-2004 (Manios et al., 2008) 
     
Hungary Boys and girls aged 11-14 years Three-day record 2005-2006 (Biro et al., 2007). Data collected in Budapest. 
     
Ireland Boys and girls aged   1 year Four-day record 2010-2011 (IUNA, online-c) 
 Boys and girls aged   2 years Four-day record 2010-2011 (IUNA, online-c) 
 Boys and girls aged   3 years Four-day record 2010-2011 (IUNA, online-c) 
 Boys and girls aged   4 years Four-day record 2010-2011 (IUNA, online-c) 
 Boys and girls aged   5-8 years Seven-day record 2003-2004 (IUNA, online-b) 
 Boys and girls aged   9-12 years Seven-day record 2003-2004 (IUNA, online-b) 
 Boys and girls aged 13-14 years Seven-day record 2005-2006 (IUNA, online-a) 
 Boys and girls aged 15-17 years Seven-day record 2005-2006 (IUNA, online-a) 
     
Italy Boys and girls aged   0-< 3 years Three-day food record 2005-2006 (Sette et al., 2010) 
 Boys and girls aged   3-< 10 years Three-day food record 2005-2006 (Sette et al., 2010) 
 Boys and girls aged 10-< 18 years Three-day food record 2005-2006 (Sette et al., 2010) 
     
The  Boys and girls aged 2-3 years Two-day record (independent days) 2005-2006 (Ocké et al., 2008) 
Netherlands Boys and girls aged 4-6 years Two-day record (independent days) 2005-2006 (Ocké et al., 2008) 
 Boys and girls aged 7-8 years Two non-consecutive 24-hour recalls 2007-2010 (van Rossum et al., 2011) 
 Boys and girls aged 9-13 years Two non-consecutive 24-hour recalls 2007-2010 (van Rossum et al., 2011) 
 Boys and girls aged 14-18 years Two non-consecutive 24-hour recalls 2007-2010 (van Rossum et al., 2011) 
     
Norway Children aged 2 years Food Frequency Questionnaire 2007 (Kristiansen and Andersen, 2009) 
 Boys and girls aged   4 years Four-day record 2000 (Elmadfa et al., 2009b) 
 Boys and girls aged   9 years Four-day record 2000 (Øverby and Andersen, 2002; Elmadfa et al., 2009b) 
 Boys and girls aged 13 years Four-day record 2000 (Øverby and Andersen, 2002; Elmadfa et al., 2009b) 
 Boys and girls aged 16-19 years Food Frequency Questionnaire 1997 (Johansson and Sovoll, 1999) 
     
Poland Boys and girls aged   1-3 years 24-hour recall 2000 (Szponar et al., 2003) 
 Boys and girls aged   4-6 years 24-hour recall 2000 (Szponar et al., 2003) 
 Boys and girls aged   7-9 years 24-hour recall 2000 (Szponar et al., 2003) 
 Boys and girls aged 10-12 years 24-hour recall 2000 (Szponar et al., 2003) 
 Boys and girls aged 13-15 years 24-hour recall 2000 (Szponar et al., 2003) 
 Boys and girls aged 16-18 years 24-hour recall 2000 (Szponar et al., 2003) 
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Country Population Dietary assessment method Year of 
survey 
Reference 
     
Portugal Boys and girls aged 13 years Food Frequency Questionnaire 2003-2004 (Elmadfa et al., 2009b) 
     
Slovenia Boys and girls aged 14-16 years Food Frequency Questionnaire 2003-2005 (Elmadfa et al., 2009b) 
     
Spain Boys and girls aged 10-14 years Two non-consecutive 24-hour recalls 2002-2003 (Elmadfa et al., 2009b). Data collected in Catalonia. 
 Boys and girls aged 15-18 years Two non-consecutive 24-hour recalls 2002-2003 (Elmadfa et al., 2009b). Data collected in Catalonia. 
     
Sweden Boys and girls aged   4 years Four-day record 2003 (Enghardt-Barbieri et al., 2006) 
 Boys and girls aged   8-9 years Four-day record 2003 (Enghardt-Barbieri et al., 2006) 
 Boys and girls aged 11-12 years Four-day record 2003 (Enghardt-Barbieri et al., 2006) 
     
United Boys and girls aged   6-9 mo Seven-day record 1986 (Mills and Tyler, 1992) reported in (Noble et al., 2001).  
Kingdom Boys and girls aged   1.5-3 years Four-day food diary 2008-2010 (Bates et al., 2011) 
 Boys and girls aged   4-10 years Four-day food diary 2008-2010 (Bates et al., 2011) 
 Boys and girls aged 11-18 years Four-day food diary 2008-2010 (Bates et al., 2011) 
mo: months 
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Appendix 2B. Vitamin C intake among children aged ~0-3 years in European countries 
Country Age 
(years) 
N Vitamin C intake excluding supplements 
(mg/day) 
   mean SD P5–P95 
Infants and/or young children      
Boys      
Belgium 2.5-3  102   91.02 46.06  
Denmark 1-3  129   55   0.4(a) 25-104 
Finland 1(b)  257   80 34  
 2  112   54 33  
 3  236   67 44  
The Netherlands 2-3  327   68  33–115  
Norway 2  829   68 40  
Poland 1-3    70   55 48  
United Kingdom 6-9 mo  130 114   
Girls      
Belgium 2.5-3    95   90.16 39.68  
Denmark 1-3  149   64   0.3(a) 23-81 
Finland 1(b)  198   75 31  
 2  118   53 30  
 3  235   60 38  
The Netherlands 2-3  313   62  32–102  
Norway 2  826   64 36  
Poland 1-3   48   44 35  
United Kingdom 6-9 mo  128 119   
Infants and/or young children (both 
sexes) 
     
Bulgaria 1-3  154   52.5 47.9  
France 1-3 mo    64   60 13  
 4 mo    60   79 21  
 5 mo   69   83 29  
 6 mo    58   80 27  
 7 mo    66   86 29  
 8-9 mo    67   92 40  
 10-12 mo    63   76 34  
 13-18 mo    66   74 35  
 19-24 mo    66   59 33  
 25-30 mo    65   54 32  
 31-36 mo    62   55 33  
Greece 1-5 2 317(c)   70 n.a. 54–88(d) 
Ireland 1  126   75(e) 44(e)  
 2  124   85(e) 64(e)  
 3  126   85(e) 45(e)  
Italy(f) 0-<3    52   90 58 28–205 
United Kingdom 1.5-3  219   67.3 41.1 19.1-159.6(g) 
     73.1(e) 55.0(e) 20.2–192.6(e) 
(a): SE. 
(b): Breast-fed children not included. 
(c): Under-reporters excluded. 
(d): P10–P90. 
(e): Including supplements. 
(f): Including fortified foods but excluding supplements. 
(g): P2.5–P97.5. 
n.a.: not available 
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Appendix 2C. Vitamin C intake among children aged ~4-6 years in European countries 
Country Age 
(years) 
N Vitamin C intake excluding supplements 
(mg/day) 
   mean SD P5–P95 
Boys      
Belgium 4-6.5 236   97.05 48.83  
Czech Republic 4-6 641 157 95  
Denmark 4-5   81   88 41 37–151  
Finland 4 307   60 41  
 6 364   72 49  
Germany(a) 6 102   91 45 27–176  
The Netherlands 4-6 327   71  35–118  
Norway(a) 4 206   81 44  
Poland 4-6   82   66 46  
Sweden 4 302   90 71 23–182  
United Kingdom 4-10 210   86.9 49.4 22.3–199.1(b) 
     95.6(a) 58.5(a) 22.3–239.5(a,b) 
Girls      
Belgium 4-6.5 228   90.54 36.30  
Czech Republic 4-6 446 157 95  
Denmark 4-5   78   78 32 31–138  
Finland 4 247   61 41  
 6 349   61 36  
Germany(a) 6 102   91 51 32.6–190 
The Netherlands 4-6 312   65  29–112  
Norway(a) 4 185   88 41  
Poland 4-6   84   61 50  
Sweden 4 288   88 74 29–155  
United Kingdom 4-10 213   86.5 49.7 17.5–193.0(b) 
     92.2(a) 54.5(a) 17.5–206.3(a,b) 
Both sexes      
Bulgaria 3-6 199   70.8 62.6  
Ireland 4 124   94(a) 53(a)  
(a): Supplements included. 
(b): P2.5–P97.5. 
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Appendix 2D. Vitamin C intake among children aged ~7-9 years in European countries 
Country Age 
(years) 
N Vitamin C intake excluding supplements 
(mg/day) 
   mean SD P5–P95 
Boys      
Austria 7-9 146 125   92  
Czech Republic 7-9 940 172 113  
Denmark 6-9 172 101   53 37–210  
France 3-10 n.a.   69.7   45.5  
Germany(a) 7-9 321 110   60 32–221  
Ireland 5-8 145   70   39 19–135 
     81(a)   48(a) 21–168(a) 
The Netherlands 7-8 153   73(b)  32–144  
Norway(a) 9 402 102   56  
Poland 7-9 101   77   71  
Sweden 8-9 444   88   68 23–184  
Girls      
Austria 7-9 146 110   73  
Czech Republic 7-9 765 172 113  
Denmark 6-9 151   91   38 41–161  
France 3-10 n.a.   72.8   42.4  
Germany(a) 7-9 321 108   69 24.6–261  
Ireland 5-8 151   75 
  85(a) 
  47 
  56(a) 
23–175 
24–196(a) 
The Netherlands 7-8 151   82(b)  37–158  
Norway(a) 9 408   95   55  
Poland 7-9 103   71   55  
Sweden 8-9 445   86   83 24–174  
Both sexes      
Bulgaria 6-10 235   96.9   75.1  
Italy(c) 3-< 10 193 107   64 26–236  
(a): Supplements included. 
(b): Median (mean not available). 
(c): Including fortified foods but excluding supplements. 
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Appendix 2E. Vitamin C intake among children aged ~10-14 years in European countries 
Country Age 
(years) 
N Vitamin C intake excluding supplements 
(mg/day) 
   mean SD P5–P95 
Boys      
Austria 10-14 248 113   96  
Bulgaria 10-14 167 114   85.5  
Denmark 10-13 164 103   61 37–230  
France 11-14 n.a.   90.1   44.0  
Germany(a) 10-11 199 119 108 27.6–257 
 12 114 172 102 37.9–163 
 13-14 214 197 135 61.2–407 
Hungary 11-14 124   99.3   78.9  
Ireland 9-12 148   74   45 21–168 
     91(a)   90(a) 21–220(a) 
 13-14   95   80   46 19–159 
     95(a)  74(a) 25–224(a) 
The Netherlands 9-13 351   85(b)  39–165  
Norway(a) 13 490 106   74  
Poland 10-12 128   71   63  
 13-15 118 106   89  
Portugal 13 987 161   94  
Spain 10-14   66   73   34  
Sweden 11-12 517   82 120 16–182  
United Kingdom 11-18 238   89.7   65.1 15.9–256.3(c) 
     94.4(a)   79.3(a) 15.9-312.0(a,c) 
Girls      
Austria 10-14 248 113   67  
Bulgaria 10-14 180 102   77.1  
Denmark 10-13 196 101   59 35–204  
France 11-14 n.a.   78.5   37.3  
Germany(a) 10-11 199 110   61 30.8–213 
 12 114 222 243 57.5–400 
 13-14 214 201   12 57.9–502 
Hungary 11-14 111   94.3   69.9  
Ireland 9-12 150   79   50 23–173 
     92(a)   68(a) 25–216(a) 
 13-14   93   69   44 22–164 
     89(a)   80(a) 22–210(a) 
The Netherlands 9-13 352   82(b)  37–160  
Norway(a) 13 515 103   81  
Poland 10-12 121   85   81  
 13-15 134   95   92  
Portugal 13 987 170   96  
Spain 10-14   53   77   37  
Sweden 11-12 499   78   79 18–180  
United Kingdom 11-18    79.0   52.2 17.7–209.2(c) 
     84.4(a)   74.9(a) 17.7–239.6(a,c) 
(a): Supplements included. 
(b): Median (mean not available). 
(c): P2.5–P97.5. 
Dietary Reference Values for vitamin C
 
EFSA Journal 2013;11(11):3418 57
Appendix 2F. Vitamin C intake among adolescents aged ~15-18 years in European countries 
Country Age 
(years) 
N Vitamin C intake excluding supplements 
(mg/day) 
   mean SD P5–P95 
Boys      
Austria > 13 1 527   91   96  
Belgium 15-18    405   89.7   42.1 59.0–113.0(a) 
Bulgaria 14-18    178 108   79.4 
Denmark 14-17    101 100   54 26–195  
France 15-17 n.a.   77.2   34.8  
Germany(b) 15-19    506   87(c)  
Ireland 15-17    129   85   60 17–211 
   101(d)   96(d) 18–245(d) 
Italy(e) 10-< 18    108 136   93 36–312  
The Netherlands 14-18    352   92(f)  43–176  
Norway 16-19     86 129   
Poland 16-18    130 121   83  
Slovenia 14-17 1 010 146 105  
Spain 15-18     61   73   28  
Girls      
Austria > 13 1 422   90   93  
Belgium 15-18    401   87.7   38.4 60.0–109.0(a) 
Bulgaria 14-18    190   92.6   78.2 
Denmark 14-17    134   95   50 26–183  
France 15-17 n.a.   91.0   48.0  
Germany(b) 15-19    536   87(c)  
Ireland 15-17    124   75   50 20–181 
     94(d) 113(d) 20–208(d) 
Italy(e) 10-< 18    139 128   92 30–286  
The Netherlands 14-18    354   84(f)  38–161  
Norway 16-19     92 119   
Poland 16-18    122   91   67  
Slovenia 14-17 1 214 149   85  
Spain 15-18     57   75   28  
(a): P25-P75. 
(b): Including fortified foods but excluding supplements. 
(c): Median. 
(d): Supplements included. 
(e): Including fortified foods but excluding supplements. 
(f): Median (mean not available). 
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Appendix 3A. Population, methods and period of dietary assessment in adults in European countries 
Country Population Dietary assessment method Year of survey Reference 
Austria Males and females aged 19-64 years 24-hour recall 2005-2006 (Elmadfa et al., 2009a; Elmadfa et al., 2009b) 
 Males and females aged 65 years and over Three-day record 2007-2008 (Elmadfa et al., 2009a; Elmadfa et al., 2009b) 
     
Belgium Males and females aged 19-59 years Two non consecutive 24-hour recalls 2004-2005 (De Vriese et al., 2006) 
 Males and females aged 60-74 years Two non consecutive 24-hour recalls 2004-2005 (De Vriese et al., 2006) 
 Males and females aged 75 years and over Two non consecutive 24-hour recalls 2004-2005 (De Vriese et al., 2006) 
     
Bulgaria Males and females aged 18-30 years 24-hour recall 1998 (Abrasheva et al., 1998) 
 Males and females aged 30-60 years 24-hour recall 1998 (Abrasheva et al., 1998) 
 Males and females aged 60-75 years 24-hour recall 1998 (Abrasheva et al., 1998) 
 Males and females aged >75 years 24-hour recall 1998 (Abrasheva et al., 1998) 
Czech     
Republic Males and females aged 19-64 years 24-hour recall 2000-2001 (Cifková and Škodová, 2004; Elmadfa et al., 2009b) 
     
Denmark Males and females aged 18-75 years Seven-day record 2003-2008 (Pedersen et al., 2010) 
 Males and females aged 18-24 years Seven-day record 2003-2008 (Pedersen et al., 2010) 
 Males and females aged 25-34 years Seven-day record 2003-2008 (Pedersen et al., 2010) 
 Males and females aged 35-44 years Seven-day record 2003-2008 (Pedersen et al., 2010) 
 Males and females aged 45-54 years Seven-day record 2003-2008 (Pedersen et al., 2010) 
 Males and females aged 55-64 years Seven-day record 2003-2008 (Pedersen et al., 2010) 
 Males and females aged 65-75 years Seven-day record 2003-2008 (Pedersen et al., 2010) 
     
Estonia Males and females aged 19-64 years 24-hour recall 1997 (ECOHOST/WHO, 1999; Elmadfa et al., 2009b) 
 Males and females aged 19-34 years 24-hour recall 1997 (ECOHOST/WHO, 1999) 
 Males and females aged 35-49 years 24-hour recall 1997 (ECOHOST/WHO, 1999) 
 Males and females aged 50-64 years 24-hour recall 1997 (ECOHOST/WHO, 1999) 
     
Finland Males and females aged 25-64 years 48-hour recall 2007 (Paturi et al., 2008; Pietinen et al., 2010) 
 Males and females aged 25-34 years 48-hour recall 2007 (Paturi et al., 2008) 
 Males and females aged 35-44 years 48-hour recall 2007 (Paturi et al., 2008) 
 Males and females aged 45-54 years 48-hour recall 2007 (Paturi et al., 2008) 
 Males and females aged 55-64 years 48-hour recall 2007 (Paturi et al., 2008) 
 Males and females aged 65-74 years 48-hour recall 2007 (Paturi et al., 2008) 
     
France Males and females aged 18-79 years Seven-day record 2006-2007 (Afssa, 2009) 
 Males and females aged 18-34 years Seven-day record 2006-2007 (Afssa, 2009) 
 Males and females aged 35-54 years Seven-day record 2006-2007 (Afssa, 2009) 
 Males and females aged 55-79 years Seven-day record 2006-2007 (Afssa, 2009) 
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Country Population Dietary assessment method Year of survey Reference 
     
Germany Males and females aged 15-80 years Two non-consecutive 24-hour recalls  2005-2006 (DGE, 2012) 
 Males and females aged 19-24 years Two non-consecutive 24-hour recalls  2005-2006 (DGE, 2012) 
 Males and females aged 25-34 years Two non-consecutive 24-hour recalls  2005-2006 (DGE, 2012) 
 Males and females aged 35-50 years Two non-consecutive 24-hour recalls  2005-2006 (DGE, 2012) 
 Males and females aged 51-64 years Two non-consecutive 24-hour recalls  2005-2006 (DGE, 2012) 
 Males and females aged 65-80 years Two non-consecutive 24-hour recalls  2005-2006 (DGE, 2012) 
     
Greece Males and females aged 22 ± 2 years 24-hour recall  1989-2001 (Elmadfa et al., 2009b). Data from the EPIC Greek cohort 
Hungary Males and females aged 18-59 years Three-day record 2003-2004 (Zajkas et al., 2007; Elmadfa et al., 2009b) 
 Males and females aged 18-34 years Three-day record 2003-2004 (Zajkas et al., 2007; Elmadfa et al., 2009b) 
 Males and females aged 35-59 years Three-day record 2003-2004 (Zajkas et al., 2007; Elmadfa et al., 2009b) 
 Males and females aged 60 years and over Three-day record 2003-2004 (Zajkas et al., 2007; Elmadfa et al., 2009b) 
     
Ireland Males and females aged 18-64 years Four-day record 2008-2010 (IUNA, 2011) 
 Males and females aged 18-35 years Four-day record 2008-2010 (IUNA, 2011) 
 Males and females aged 36-50 years Four-day record 2008-2010 (IUNA, 2011) 
 Males and females aged 51-64 years Four-day record 2008-2010 (IUNA, 2011) 
 Males and females aged 65-90 years  Four-day record 2008-2010 (IUNA, 2011) 
     
Italy Males and females aged 18-< 65years Three-day food record 2005-2006 (Sette et al., 2010) 
 Males and females aged 65 years and over Three-day food record 2005-2006 (Sette et al., 2010) 
 Males and females aged 0-99 years Three-day food record 2005-2006 (Sette et al., 2010). Supplementary information on dietary supplements. 
     
Latvia Males and females aged 17-26 years Two non-consecutive 24-hour recalls + food 
frequency questionnaire 
2008 (Joffe et al., 2009) 
 Males and females aged 27-36 years Two non-consecutive 24-hour recalls + food 
frequency questionnaire 
2008 (Joffe et al., 2009) 
 Males and females aged 37-46 years Two non-consecutive 24-hour recalls + food 
frequency questionnaire 
2008 (Joffe et al., 2009) 
 Males and females aged 47-56 years Two non-consecutive 24-hour recalls + food 
frequency questionnaire 
2008 (Joffe et al., 2009) 
 Males and females aged 57-64 years Two non-consecutive 24-hour recalls + food 
frequency questionnaire 
2008 (Joffe et al., 2009) 
     
Lithuania Males and females aged 19-64 years 24-hour recall 2007 (Elmadfa et al., 2009b) 
     
The  Males and females aged 19-30 years Two non-consecutive 24-hour recalls 2007-2010 (van Rossum et al., 2011) 
Netherlands Males and females aged 31-50 years Two non-consecutive 24-hour recalls 2007-2010 (van Rossum et al., 2011) 
 Males and females aged 51-69 years Two non-consecutive 24-hour recalls 2007-2010 (van Rossum et al., 2011) 
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Country Population Dietary assessment method Year of survey Reference 
     
Norway Males and females aged 18-70 years Two randomly distributed 24-hour recalls + Food 
Propensity Questionnaire
2010-2011 (Holm Totland et al., 2012) 
 Males and females aged 18-29 years Two randomly distributed 24-hour recalls + Food 
Propensity Questionnaire
2010-2011 (Holm Totland et al., 2012) 
 Males and females aged 30-39 years Two randomly distributed 24-hour recalls + Food 
Propensity Questionnaire
2010-2011 (Holm Totland et al., 2012) 
 Males and females aged 40-49 years Two randomly distributed 24-hour recalls + Food 
Propensity Questionnaire
2010-2011 (Holm Totland et al., 2012) 
 Males and females aged 50-59 years Two randomly distributed 24-hour recalls + Food 
Propensity Questionnaire
2010-2011 (Holm Totland et al., 2012) 
 Males and females aged 60-70 years Two randomly distributed 24-hour recalls + Food 
Propensity Questionnaire
2010-2011 (Holm Totland et al., 2012) 
     
Poland Males and females aged 19-25 years 24-hour recall 2000 (Szponar et al., 2003) 
 Males and females aged 26-60 years 24-hour recall 2000 (Szponar et al., 2003) 
 Males and females aged 61 years and over 24-hour recall 2000 (Szponar et al., 2003) 
     
Portugal Males and females aged 18-≥ 65 years Food frequency questionnaire 1999-2003 (Lopes et al., 2006; Elmadfa et al., 2009b). Data collected in Porto. 
 Males and females aged 18-39 years Food frequency questionnaire 1999-2003 (Lopes et al., 2006). Data collected in Porto 
 Males and females aged 40-49 years Food frequency questionnaire 1999-2003 (Lopes et al., 2006). Data collected in Porto 
 Males and females aged 50-64 years Food frequency questionnaire 1999-2003 (Lopes et al., 2006). Data collected in Porto 
 Males and females aged 65 years and over Food frequency questionnaire 1999-2003 (Lopes et al., 2006; Elmadfa et al., 2009b). Data collected in Porto. 
     
Romania Males and females aged 19-64 years Personal interview 2006 (Elmadfa et al., 2009b) 
 Males and females aged 65 years and over Personal interview 2006 (Elmadfa et al., 2009b) 
     
Spain Males and females aged 18-24 years Two non-consecutive 24-hour recalls 2002-2003 (Serra-Majem et al., 2007). Data collected in Catalonia. 
 Males and females aged 24-44 years Two non-consecutive 24-hour recalls 2002-2003 (Serra-Majem et al., 2007). Data collected in Catalonia 
 Males and females aged 45-64 years Two non-consecutive 24-hour recalls 2002-2003 (Serra-Majem et al., 2007). Data collected in Catalonia 
 Males and females aged 65-75 years Two non-consecutive 24-hour recalls 2002-2003 (Serra-Majem et al., 2007). Data collected in Catalonia 
     
Sweden Males and females aged 18-80 years Four-day record 2010-2011 (Amcoff et al., 2012) 
 Males and females aged 18-30 years Four-day record 2010-2011 (Amcoff et al., 2012) 
 Males and females aged 31-44 years Four-day record 2010-2011 (Amcoff et al., 2012) 
 Males and females aged 45-64 years Four-day record 2010-2011 (Amcoff et al., 2012) 
 Males and females aged 65-80 years Four-day record 2010-2011 (Amcoff et al., 2012) 
     
United  Males and females aged 19-64 years Four-day food diary 2008-2010 (Bates et al., 2011) 
Kingdom Males and females aged 65 years and over Four-day food diary 2008-2010 (Bates et al., 2011) 
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Appendix 3B. Vitamin C intake among adults aged ~19-65 years in European countries 
Country Age 
(years) 
N Vitamin C intake excluding 
supplements (mg/day) 
Vitamin C intake including 
supplements 
(mg/day) 
   mean SD P5–P95 mean SD P5–P95 
Men       
Austria 19-64    778 130 120    
Belgium 19-59    413   87.5   32.4 64.0–106.0(a)   
Czech Republic 19-64 1 064 111 119    
Denmark 18-75 1 569 102   54 47–163(b)    
Estonia 19-64    899   82   96    
Finland 25-64    730   98   88    
France 18-79    776   91.3   55.5    
Germany 15-80 6 160   96(c)    
Hungary 18-> 60    473   79   50    
Ireland 18-64    634   81   55 19–192  114 152 19–310  
Italy 18-64.9 1 068 126   79 38–275     
Lithuania 19-64    849   69   53     
Norway 18-70    862 105   77 n.a.-258    
Portugal 18-≥ 65    917 116   53.9 51.5–219    
Romania 19-64    177   82   48     
Sweden 18-80    792   93   57 23–193     
United Kingdom 19-64    346   91.4   71.5 12.7–259.3(d) 101.3   89.6 12.7–288.5(d) 
Women         
Austria 19-64 1 345 133 105     
Belgium 19-59    460   91.2   39.1 63.0–114.0(a)    
Czech Republic 19-64 1 094 138 142     
Denmark 18-75 1 785 114   63 50–190(b)    
Estonia 19-64 1 113   82   81     
Finland 25-64    846 118   82     
France 18-79 1 142   94.3   48.7     
Germany 15-80 7 593   97(c)     
Hungary 18-> 60    706   80   52     
Ireland 18-64    640   79   51 18–184  141 304 20–474  
Italy 18-64.9 1 245 123   74 35–259     
Lithuania 19-64 1 087   66   62     
Norway 18-70    925 111   71 n.a.-243    
Portugal 18-≥ 65 1 472 131   62.6 51.6–235     
Romania 19-64    341   76   41     
Sweden 18-80 1 005   96   53 29–194     
United Kingdom 19-64    461   87.6   66.7 15.6–237.2(d) 122.1 149.6 15.6–545.8(d) 
(a): P25-P75. 
(b): P10-P90. 
(c): Median, including fortified foods but excluding supplements. 
(d): P2.5–P97.5. 
n.a.: not available 
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Appendix 3C. Vitamin C intake among adults aged ~19-34 years in European countries 
Country Age 
(years) 
N Vitamin C intake excluding supplements 
(mg/day) 
   mean SD P5–P95 
Men      
Bulgaria 18-30 208   99.8   82.2  
Denmark 18-24 105   96   47 31–194 
 25-34 234 111   63 48–212 
Estonia 19-34 396   85 105  
Finland 25-34 137 103   97  
France 18-34 n.a.   90.3   66.7  
Germany(a) 19-24 
25-34 
469 
614 
  90(b)
  91(b) 
  
Greece 22 ± 2 500 146(c) 130(c)  
Hungary 18-34 136   77   49.9  
Ireland 18-35 276   84   59 17–213 
   129(c) 168(c) 17–506(c) 
The Netherlands 19-30 356   96(d)  45–180  
Norway 18-29 138 102   77  
 30-39 136 107   88  
Poland 19-25 191 117   97.1  
Portugal 18-39 179 127   63.8 51.5–230 
Spain 18-24 127   73.9   
 25-44 326   93.1   
Sweden 18-30 132   78   59 11-187 
      
Women      
Bulgaria 18-30 204   94.2   78.9  
Denmark 18-24 150 109   56 41–235  
 25-34 340 118   67 42–248 
Estonia 19-34 459   89   76  
Finland 25-34 180 101   70  
France 18-34 n.a.   82.1   45.7  
Germany(a) 19-24 486   87(b)  
 25-34 852   92(b)   
Greece 22 ± 2 451 145(c) 120(c)  
Hungary 18-34 176   77.3   59.3  
Ireland 18-35 255   74   51 16–178 
   146(c) 384(c) 17–536(c)   
The Netherlands 19-30 347   86(d)  39–165  
Norway 18-29 143   97   67  
 30-39 169 116   76  
Poland 19-25 211   82.1   60.7  
Portugal 18-39 299 136   70.4 55.1–237  
Spain 18-24 182   78.6   
 25-44 376   96.7   
Sweden 18-30 202   83   48 18-168 
      
Both sexes      
Latvia(c) 17-26 378   98.72   
 27-36 206   93.79   
(a): Including fortified foods but excluding supplements. 
(b): Median. 
(c): Supplements included. 
(d): Median (mean not available). 
n.a.: not available 
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Appendix 3D. Vitamin C intake among adults aged ~35-64 years in European countries 
Country Age 
(years) 
N Vitamin C intake excluding supplements 
(mg/day) 
   mean SD P5–P95 
Men      
Bulgaria 30-60    224 106   84.9  
Denmark 35-44    318   98   50 37–188  
 45-54    336 105   57 37–216  
 55-64    336 104   51 36–202 
Estonia 35-49    319   84   93  
 50-64    185   69   81  
Finland 35-44    177   96   86  
 45-54    190   99   85  
 55-64    226   96   87  
France 35-54    n.a.   86.2   44.4  
Germany(a) 35-50 1 946   97(b)  
 51-64 1 460   102(b)   
Hungary 35-59    199   79.4   47.6  
Ireland 36-50    205   77   53 19–182  
     96(c) 106(c) 19–274(c)  
 51-64    153   78   49 20–178 
   113(c) 170(c) 20–296(c)   
The Netherlands 31-50    348   95(d)  44–180 
 51-69    351   90(d)  42–172   
Norway 40-49    179   96   64  
 50-59    192 104   70  
Poland 26-60    865   94.4   81.1  
Portugal 40-49    197 117   60.5 49.7–229  
 50-64    295 114   49.8 52.9–212 
Spain 45-64    265 110   
Sweden 31-44    183   87   49 25–179 
 45-64    308   94   59 24–199  
      
Women      
Bulgaria 30-60    224   95.1   75.5  
Denmark 35-44    412 114   67 40–222  
 45-54    359 112   62 38–222  
 55-64    326 117   62 41–228 
Estonia 35-49    376   86   91  
 50-64    280   65   74  
Finland 35-44    211 110   76  
 45-54    232 128   93  
 55-64    223 130   82  
France 35-54    n.a.   82.1   45.7  
Germany(a) 35-50 2 648   96(b)  
 51-64 1 740   103(b)   
Hungary 35-59    295   86.4   55.6  
Ireland 36-50    232   80   50 20–182 
   103(c) 108(c) 22–256(c)  
 51-64    153   87   53 22–202 
   192(c) 344(c) 24–1,082(c)    
The Netherlands 31-50    351   89(d)  41–171  
 51-69    353   94(d)  44–178 
Norway 40-49    256 111   66  
 50-59    193 113   74  
Poland 26-60 1 035   80.4   70.8  
Portugal 40-49    340 138   62.4 60.6–248  
 50-64    494 133   60.5 51.6–241 
Spain 45-64    337 135   
Sweden 31-44    247   90   53 33–183 
 45-64    358 101   52 30–197 
      
Both sexes      
Latvia(c) 37-46    272   93.69   
 47-56    304   96.28   
 57-64    217   87.28   
(a): Including fortified foods but excluding supplements. 
(b): Median. 
(c): Supplements included. 
(d): Median (mean not available). 
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Appendix 3E. Vitamin C intake among adults aged ~65 years and over in European countries 
Country Age 
(years) 
N Vitamin C intake excluding supplements 
(mg/day) 
   mean SD P5–P95 
Men      
Austria > 64    147 102   59  
Belgium 60-74    416   94.5   40.8 65.0–118.0(a) 
 > 75    389   86.4   43.6 55.0–110.0(a) 
Bulgaria 60-75    186   89.1   69.8  
 > 75    101   85.8   61.0  
Denmark 65-75    240   96   51 38–198  
Finland 65-74    229   92   72  
France 55-79    n.a.   96.1   60.1  
Germany(b) 65-80 1 165   98(c)  
Hungary ≥ 60    138   79   52.8  
Ireland ≥ 65    106   72   52 14–174  
   102(d) 146(d) 14–347(d) 
Italy ≥ 65    202 127   74 43–261  
Norway 60-70    217 115   84  
Poland > 60    226   76.7   60.6  
Portugal ≥ 65    246 121   57.3 56.8–227  
Romania > 64    177   77   39  
Spain 65-75    122 122   
Sweden 65-80    169 110   57 37–211  
United Kingdom ≥ 65     96   85.7   50.1 18.5–238.6(e) 
   109.7(d) 104.9(d) 18.5–314.8(d,e) 
   
Women      
Austria > 64    202 115   60  
Belgium 60-74    406 92.1 52.3 55.0–117.0(a) 
 > 75    355 86.3 41.7 56.0–110.0(a) 
Bulgaria 60-75    194   83.2   69.8  
 > 75    113   79.4   64.9  
Denmark 65-75    198 104   55 30–208  
Finland 65-74    234   97   68  
France 55-79    n.a. 104   52  
Germany(b) 65-80 1 331 100(c)  
Hungary ≥ 60    235   72.4   39.9  
Ireland ≥ 65    120   81   46 23–189 
   132(d) 333(d) 23–358(d) 
Italy ≥ 65    316 127   84 34–282  
Norway 60-70    164 115   72  
Poland > 60    365   68.8   53.2  
Portugal ≥ 65    339 118   56.5 46.7–212  
Romania > 64    341   76   40  
Spain 65-75    122 119   
Sweden 65-80    198 108   57 38-216  
United Kingdom ≥ 65    128   80.3   49.8 14.0–200.0(e) 
     96.7(d)   87.2(d) 14.0–338.0(d,e) 
(a): P25-P75. 
(b): Including fortified foods but excluding supplements. 
(c): Median. 
(d): Supplements included. 
(e): P2.5-P97.5. 
n.a.: not available 
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Appendix 4. Vitamin C concentration of human milk from healthy mothers not taking supplements 
Reference N 
(number of 
samples) 
Country Maternal intake Maternal plasma Stage of lactation Vitamin C concentration (mg/L) Range (mg/L) 
   (mg/day);  
mean ± SD 
(µmol/L); 
mean ± SD 
 mean ± SD median  
Byerley and 
Kirksey (1985) 
5(a) (5) USA 156 ± 115 Not reported 7-20 weeks ~83 ± 30.5(b)  ~47-122(b) 
Daneel-Otterbech 
et al. (2005) 
142(a) (142) Switzerland Not reported Not reported 1.0-21.8 months 61.6 ± 13.6(c)   
Ortega et al. 
(1998a) 
41 (d) 
 
16 (e) 
  
Spain 149.7 ± 73.2 
 
152.4 ± 97.9  
84.1 ± 168.7 (f)
 
73.3 ± 84.2 (f) 
13-14 days 
40 days 
13-14 days 
40 days 
76.0 ± 52.1(g) 
87.4 ± 57.3(g) 
41.2 ± 35.7(g) 
42.5 ± 51.6(g) 
  
Ortega et al. 
(1998b)  
12(h) (24) Spain < 80(i) 30.1 ± 36.3 (b) 13-14 days 
40 days 
39.7 ± 38.8(c) 
89.0 ± 67.8(c) 
40.0(c) 
79.7(c) 
 
Salmenpera (1984) 200(d) (565) Finland 138 
range: 48-277 
 
58.5 ± 19.3(g) 
48.8 ± 22.1(g) 
54.5 ± 26.1(g) 
53.9 ± 24.4(g) 
60.8 ± 26.7(g) 
61.3 ± 26.7(g) 
0 months 
2 months 
4 months 
6 months 
9 months 
12 months 
61.8 ± 9.9 
59.1 ± 11.8 
49.7 ± 10.6 
46.8 ± 10.2 
44.6 ± 5.6 
41.4 ± 11.3 
  
Sneed et al. (1981) 7(a) USA   83 ± 55 
152 ± 115 
43.7 ± 33.5(g) 
49.4 ± 14.8(g) 
5-7 days 
43-45 days 
53.1 ± 17.1 
61.0 ± 10.2 
  
Thomas et al. 
(1980) 
6(a) USA 131 ± 88 31.0 ± 18.2(g) 6 months 35.2 ± 12.0   
(a): smoking status not reported. 
(b): estimated from figure. 
(c): calculated using a correction for the density of milk of 1.032 g/mL according to Neville et al. (1988). 
(d): non-smokers. 
(e): smokers. Among them, three subjects took supplements (mean intake of vitamin C from supplements 30 ± 79.9 mg/day). 
(f): serum. 
(g): calculated using a conversion factor of 5.678 (Young and Huth, 1998). 
(h): smokers (~24 %) and non-smokers. 
(i): data for intakes ≥ 80 mg/day excluded as included women taking supplements. 
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ABBREVIATIONS 
Afssa Agence française de sécurité sanitaire des aliments 
AI Adequate Intake 
AR Average Requirement 
BMD Bone mineral density 
BMI Body mass index 
CC Case control 
CHD Coronary heart disease 
CI Confidence interval 
COMA Committee on Medical Aspects of Food Policy 
CRP C-reactive protein 
CV Coefficient of variation 
CVD Cardiovascular disease 
d day 
D-A-CH Deutschland- Austria- Confoederatio Helvetica 
DBP Diastolic blood pressure 
DNA Deoxyribonucleic acid 
DH Department of Health 
DR Dietary recall 
DRV Dietary Reference Value 
EAR Estimated Average Requirement 
EC European Commission 
EFSA European Food Safety Authority 
EPIC European Prospective Investigation into Cancer and Nutrition 
EU European Union 
EURRECA EURopean micronutrient RECcommendations Aligned 
FAO Food and Agriculture Organization 
FFQ Food Frequency Questionnaire 
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GLUT Glucose transporter 
GST Glutathion-S-transferase 
Hp Haptoglobin 
IOM U.S. Institute of Medicine of the National Academy of Sciences 
LDL Low-density lipoprotein 
LRNI Lower Reference Nutrient Intake 
LTI Lowest Threshold Intake 
m male 
MI Myocardial infarction 
NADH reduced nicotinamide adenine dinucleotide  
NADPH reduced nicotinamide adenine dinucleotide phosphate 
NNR Nordic Nutrition Recommendations 
NHANES National Health and Nutrition Examination Survey 
NRC National Research Council 
OJ Official Journal 
PRI Population Reference Intake 
RCT Randomised controlled trial 
RDA Recommended Dietary Allowance 
RI Recommended Intake 
RNI Recommended Nutrient Intake 
SBP Systolic blood pressure 
SCF Scientific Committee for Food 
SD Standard deviation 
SE Standard error 
SU.VI.MAX Supplementation en vitamines et minéraux antioxydants [French 
prospective study on supplementation with vitamins and minerals] 
SVCT Sodium-dependent vitamin C transporter  
UK United Kingdom 
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UL Tolerable Upper Intake Level 
UNU United Nations University 
US United States of America 
WCRF World Cancer Research Fund 
WHO World Health Organization 
WR Weight record method 
y year 
 
